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Rethinking FDA Regulation of Complex Products 
Philip E. Alford, PhD 
On the outside, modern pharmaceuticals may look much the 
same as they have for decades—colorful two-tone capsules, 
nondescript tablets, and mysterious names—but inside each 
dose is an increasingly complex arrangement of components. 
Today, many drugs derive their therapeutic properties not only 
from the presence of a single pharmacologically-active 
compound, but from the interplay and assembly of multiple 
active components.1 In some cases, the resulting product is so 
complex that current science is not capable of explaining all 
aspects that impart therapeutic effects.2 Even when these 
products consist solely of non-biological molecules, they can 
nonetheless bear a closer resemblance to biological and 
mechanical products than to conventional small molecule 
pharmaceuticals.3 Other complex modern products include 
 
 1. See JILL B. CONNER ET AL., Copaxone® in the Era of Biosimilars and 
Nanosimilars, in HANDBOOK OF CLINICAL NANOMEDICINE: NANOPARTICLES, 
IMAGING, THERAPY, AND CLINICAL APPLICATIONS 790 (2016); Markham C. 
Luke, Director, Division of Therapeutic Performance, U.S. Food & Drug Admin., 
Address at Generic + Biosimilar Medicines Conference (Nov. 6, 2019), 
https://accessiblemeds.org/sites/default/files/2019-11/Complex-Product-
Workshop-GRxBiosims.pdf; CROMMELIN ET AL., NON-BIOLOGICAL COMPLEX 
DRUGS THE SCIENCE AND THE REGULATORY LANDSCAPE 1–8 (2015); Xiaohui 
Jiang, Deputy Director, Division of Therapeutic Performance, Address at 
Demonstrating Equivalence of Generic Complex Drug Substances and 
Formulations (Oct. 6, 2017), https://www.fda.gov/media/108937/download; 
OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT (2020), 
https://www.fda.gov/media/135329/download; U.S. FOOD & DRUG AMIN., 
GENERIC DRUG USER FEE AMENDMENTS (GDUFA) SCIENCE AND RESEARCH 
PRIORITY INITIATIVES FOR FISCAL YEAR 2020 (2019), 
https://www.fda.gov/media/132370/download; see also Vinod Shah, Non-
Biological Complex Drugs, Non-Biological Complex Drugs (NBCD) Working 
Group, Address at Complex Medicines: Science, Regulation, and Accelerating 
Development (May 13, 2019), https://www.fda.gov/media/125176/download. 
 2. See Shah, supra note 1; Teva Neuroscience, Inc. Citizen Petition, No. 
FDA-2015-P-1050-0001 (U.S. Food & Drug Admin. Apr. 1, 2015). See also 
CROMMELIN ET AL., supra note 1 at 1–8. 
 3. See Shah, supra note 1. 
478 MINN. J. L. SCI. & TECH. [Vol. 21:2 
 
combinations of drugs and devices, in which the functioning of 
the drug is linked to the output of a diagnostic test, mechanical 
delivery system, computer, or other device.4 Medicine that is 
personalized to each patient or adapts to patient outcomes is on 
the horizon.5 Other products incorporate nanotechnology-based 
materials, or operate via unfamiliar mechanisms, such that 
merely determining the appropriate regulatory framework is 
challenging.6 Each of the above could be considered a “Complex 
Product.”7 In this Note, the term Complex Products will be used 
primarily to refer to non-biologic drugs, devices, and 
combination products that involve nanotechnology-based 
features8 or operate at the boundary between drug and device.9 
Complex Products do not fall neatly into the Food and Drug 
Administration (“FDA”)’s existing regulatory schemes for drugs, 
devices, biologics, or combinations thereof. The distinction is not 
merely semantic: each product classification offers differing 
regulatory hurdles and differing mechanisms for permitting 
follow-on competition.10 For example, approval of generic non-
 
 4. U.S. FOOD & DRUG AMIN., USER INTERFACE CONSIDERATIONS FOR 
DRUG-DEVICE COMBINATION PRODUCTS SUBMITTED IN AN ANDA, 
http://pqri.org/wp-content/uploads/2017/02/6-PQRI-Chan.pdf (last visited Apr. 
16, 2020). 
 5. See id.; Press Release, U.S. Food & Drug Amin., FDA Approves Pill with 
Sensor that Digitally Tracks if Patients Have Ingested their Medication, U.S. 
FOOD & DRUG ADMIN. (Nov. 13, 2017), https://www.fda.gov/news-events/press-
announcements/fda-approves-pill-sensor-digitally-tracks-if-patients-have-
ingested-their-medication (describing Abilify MyCite as a schizophrenia drug 
that contains a sensor in each pill that records that the medication was taken 
and reports to a wearable patch, embedded in the pill, that records that the 
medication was taken). 
 6. See C. Lee Ventola, Progress in Nanomedicine: Approved and 
Investigational Nanodrugs, 42 PHARMACY & THERAPEUTICS 723, 742–55 (2017), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720487/. 
 7. See U.S. FOOD & DRUG ADMIN., GENERIC DRUG PERFORMANCE GOALS 
AND PROCEDURES FISCAL YEARS 2018–2022 (2016), 
https://www.fda.gov/media/101052/download (defining “Complex Product”). 
 8. Id. 
 9. See discussion infra Section I(C)(ii). 
 10. In this note, the term “follow-on” refers to products or manufacturers 
seeking to replicate the success of a prior-approved product of another. This 
term is used rather than “generic,” which refers specifically to 510(k)-type drugs 
but without intending to specifically refer to generics. Examples of follow-on 
products are generics, biosimilars, and 510k devices. Follow-on companies, e.g., 
generic manufacturers, represent subsequent market entrants that serve as 
competition to bring prices down. The initial innovator is commonly referred to 
as brand side, pioneer, or innovator. 
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biologic complex drugs (NBCDs) proceeds via an abbreviated 
new drug application (ANDA) pathway. This pathway typically 
requires an identical active ingredient and equivalent 
bioavailability and bioequivalence, yet NBCDs often cannot be 
fully characterized in terms of active ingredient and 
bioavailability.11 Devices containing nanomaterials can be 
approved for market and serve as predicates upon which further 
approvals can be based, but minor variations in nanomaterials 
can result in significant changes in biological risk. Complex 
drug-device combinations can tie the functioning of a drug to the 
operation of a device, which can confound models for predicting 
bioequivalence.12 
The U.S. Government Accountability Office (GAO) has 
urged regulatory development in the area of Complex 
Products,13 but the FDA has indicated that regulatory progress 
is presently limited by current science.14 Congress has 
 
 11. See e.g., Teva Neuroscience, Inc. Citizen Petition, No. FDA-2015-P-
1050-0001 (Apr. 1, 2015), FDA-2014-P-0933-0001 (July 2, 2014); see also Teva 
Pharmaceuticals USA v. Sandoz, Inc., 573 U.S. 318 (2015); see also FDA 
Approves a Generic for Teva’s Copaxone, Bringing Longstanding Regulatory 
Battles Near an End, PHARMACEUTICAL COMMERCE (Apr. 16, 2015), 
http://www.pharmaceuticalcommerce.com/latest-news/fda-approves-a-generic-
for-tevas-copaxone-bringing-longstanding-regulatory-battles-near-an-end/. 
 12. See, e.g., IKARIA, INC. (Kleinfeld, Kaplan, and Becker, LLP) - Citizen 
Petition, https://www.regulations.gov/contentStreamer?documentId=FDA-
2013-P-0070-0001&attachmentNumber=1&contentType=pdf. (objecting to 
510k clearance for a follow-on nitric oxide delivery system; citizen petitions are 
often submitted to the FDA when an interested party is concerned that a follow-
on product will be approved despite differences in equivalency). 
 13. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-18-80, GENERIC DRUGS: 
FDA SHOULD MAKE PUBLIC ITS PLANS TO ISSUE AND REVISED GUIDANCE ON 
NONBIOLOGICAL COMPLEX DRUGS (2017), 
https://www.gao.gov/assets/690/689047.pdf; U.S. GOV’T ACCOUNTABILITY 
OFFICE, GAO-17-452, GENERIC DRUG USER FEES: APPLICATION REVIEW TIMES 
DECLINED, BUT FDA SHOULD DEVELOP A PLAN FOR ADMINISTERING ITS 
UNOBLIGATED USER FEES (2017), https://www.gao.gov/assets/690/684950.pdf 
(noting that generic competition around complex drugs poses unique scientific 
and regulatory challenges and should be a primary focus area for regulatory 
development). 
 14. See Upcoming Product-Specific Guidances for Complex Generic Drug 
Product Development, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific 
-guidances-complex-generic-drug-product-development (last updated Nov. 21, 
2019) (listing complex products for which the FDA plans to provide additional 
product specific guidances). Such guidances are in line with the FDA’s GDUFA 
II commitment letter and Congress’s mandate under FDAMA. See e.g., U.S. 
FOOD & DRUG ADMIN., supra note 7; see also FDA Reauthorization Act of 2017, 
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repeatedly pushed for the FDA to better facilitate approval of 
follow-on competition for Complex Products.15 In response, the 
FDA has focused on new efforts to bring complex generic 
products to market. By 2020, Complex Products accounted for 
eleven percent of prior-year generic approvals and more than 
fifty percent of all prior-year product specific guidances (PSGs).16 
This Note will discuss challenges surrounding Complex 
Products, particularly where such products do not find a suitable 
place in existing regulatory pathways. In part one, this Note will 
provide an overview of Complex Products, discuss the existing 
regulatory pathways for drugs, biologics, and devices, and 
explain how the FDA determines which regulatory framework 
applies to a given product. In part two, this Note will examine 
problems with the FDA’s current approach to handling Complex 
Products within its regulatory framework. In part three, this 
Note suggests rethinking the chemistry-based requirements 
written into the Food, Drug & Cosmetic Act (“FD&C Act”) and 
adjusting the delineations between product classifications. 
Lastly, this Note proposes that Congress provide an incentive to 
innovators to disclose data, tolerances, and know-how that will 
lower overall costs for development in the industry and improve 
scientific understanding of Complex Products and 
nanotechnology in medicine. 
 
Pub. L. No. 115-52, 131 Stat. 1005 (2017) (providing provisions to facilitate 
generic drug approval, including generic complex products). 
 15. See January 17, 2020 Letter to FDA Commissioner Stephen Hahn, 
Committee on Energy and Commerce, House of Representatives; see also 
GENERIC DRUG USER FEE AMENDMENTS OF 2017, TITLE III, FDA 
REAUTHORIZATION ACT OF 2017 PUB. L. 115-52, §§ 301-307, 131 STAT. 1005, 
1020-28 (2017) (providing provisions to facilitate generic drug approval, 
including of Complex Products); GENERIC COMPLEX DRUGS SAFETY AND 
EFFECTIVENESS FOR PATIENTS ACT OF 2015, H.R. 1576, 114TH CONG. (2015) 
(discussing a failed bill proposing to require a study by the Government 
Accountability Office (GAO) to assess the Food and Drug Administration’s 
current regulatory pathway for reviewing generic versions of nonbiologic 
complex drug products). 
 16. OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT (2020), 
https://www.fda.gov/media/135329/download. 
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I. BACKGROUND 
A. COMPLEX PRODUCTS AND NANOTECHNOLOGY-BASED 
PRODUCTS 
FDA efforts are increasingly focused on Complex Products, 
which can be more difficult to develop due to technological and 
regulatory uncertainty.17 In 2019, the FDA approved more than 
a hundred generic forms of Complex Products (eleven percent of 
total generic approvals in 2019) and more than half of the FDA’s 
product specific guidances (PSGs) were for Complex Products.18 
Starting in 2020, the FDA began providing a forward-looking list 
of the product specific guidances it plans to release for generic 
Complex Products. This focus is largely a response to 
congressional pressure to increase competition and reduce prices 
of Complex Products.19 However, as discussed below, the FDA is 
still exploring a precise definition for Complex Products. 
The FDA first defined Complex Products in response to 
congressional concern that the existing ANDA-type generic 
pathway was not suitable for complex modern pharmaceuticals. 
The FDA initially defined Complex Products as follows: 
1. Products with complex active ingredients (e.g., peptides, 
polymeric compounds, complex mixtures of APIs, naturally sourced 
ingredients); complex formulations (e.g., liposomes, colloids); complex 
routes of delivery (e.g., locally acting drugs such as dermatological 
products and complex ophthalmological products and optic dosage 
forms that are formulated as suspensions, emulsions or gels) or 
complex dosage forms (e.g., transdermals, metered dose inhalers, 
extended release injectables); 
2. Complex drug-device combination products (e.g., auto injectors, 
metered dose inhalers); and 
3. Other products where complexity or uncertainty concerning the 
approval pathway or possible alternative approach would benefit from 
early scientific engagement. 20 
Subsequent characterizations of Complex Products by the 
Division of Therapeutic Performance and Office of 
Pharmaceutical Quality have provided the following taxonomy: 
 
 17. Id. 
 18. Id. 
 19. See GENERIC DRUG USER FEE AMENDMENTS OF 2017, TITLE III, FDA 
REAUTHORIZATION ACT OF 2017 PUB. L. 115-52, §§ 301-307, 131 STAT. 1005, 
1020-28 (2017) (providing provisions to facilitate generic drug approval, 
including the approval of Complex Products). 
 20. See U.S. FOOD & DRUG ADMIN., supra note 7 (providing a definition for 
Complex Product). 
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complex active ingredients (e.g., mixtures of APIs, polymeric 
compounds, synthetic peptides, and naturally sourced 
ingredients), complex formulations (e.g., liposomes, suspensions, 
gels, emulsions and other colloids), complex routes of delivery 
(e.g., complex ophthalmic products, locally-acting drugs 
including dermatologic products, and inhaled products), complex 
dosage forms (e.g., long acting injectables, implantables, 
transdermals, aerosols), complex drug-device combinations (e.g., 
dry powder inhalers, metered dose inhalers, nasal sprays, 
autoinjectors), and other Complex Products (e.g., abuse 
deterrent opioid formulations).21 
The 2019 Annual Report from the Office of Generic Drugs 
and the Generic Drug User Fee Amendments (GDUFA) 
Regulatory Science Priority Initiatives for Fiscal Year 2020 
further organizes such Complex Products into three groups: 
“Complex active ingredients, formulations, and dosage forms”; 
“Complex routes of delivery”; and “Complex drug-device 
combinations.”22 
In each case, the FDA has found it easiest to define Complex 
Products by way of examples. Table 1, below, provides examples 
of Complex Products referring to the above three groups. The 
products in group “A” present challenges related to 
characterization and distribution of molecular and nanoscale 
features.23 Group “B” products involve challenges related to 
pharmacokinetics (describing absorption and distribution 
through the body) and bioequivalence (showing no difference in 
therapeutic effect compared to a reference).24 Group “C” products 
are combination products, but for which the interplay of drug 
and device is sufficiently complex that drug effects are not 
readily modeled or predicted based on the functioning of the 
device, e.g., due to ergonomics, usability, and human-factor 
 
 21. See Jiang, supra note 1; See also Katherine Tyner, Associate Director 
for Science, Office of Pharmaceutical Quality, An Overview of Complex Drug 
Substances and Complex Formulations—A Quality Perspective, 
https://pqri.org/wp-content/uploads/2019/04/2-TynerPQRI.pdf (last accessed 
Apr. 18, 2020). 
 22. See OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT (2020), 
https://www.fda.gov/media/135329/download; GENERIC DRUG USER FEE 
AMENDMENTS (GDUFA) SCIENCE AND RESEARCH PRIORITY INITIATIVES FOR 
FISCAL YEAR 2020 (2020), https://www.fda.gov/media/132370/download. 
 23. See OFFICE OF GENERIC DRUGS, 2019 ANNUAL REPORT, supra note 22. 
 24. Id. 
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effects.25 In some contexts, Complex Products have been 
described as nanomedicine.26 Indeed, the challenges in 
classifying Complex Products reflect more general challenges in 
describing the application of nanotechnology to non-biologic 
drugs and devices.27 
 
Table 1. Examples of Complex Products. 
Brand 
Product 
Generic 
Name 
Description Indication 
Author’s 
Suggested 
Complex 
Product 
Group 
Renvela®
28 
Sevelamer  
carbonate 
Mixture of 
linear, 
branched and 
crosslinked 
polymer 
structures 
Phosphorus 
control in 
patients with 
chronic kidney 
disease on 
dialysis 
A 
Doxil®29 
Liposomal 
doxorubicin 
Chemotherapy 
drug 
encapsulated 
in a nano-scale 
lipid bilayer 
vesicle 
Ovarian 
cancer, AIDS-
related 
Kaposi’s 
sarcoma, and 
multiple 
myeloma 
A and B 
 
 25. Id. 
 26. Daan J. A. Crommelin & Jon S. B. de Vlieger, Non-Biological Complex 
Drugs, in AAPS ADVANCES IN THE PHARMACEUTICAL SCIENCES SERIES 20, 1–2 
(2015). 
 27. Id. 
 28. See Renvela Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf 
(last accessed Apr. 18, 2020). 
 29. See Doxil Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf 
(last accessed Apr. 18, 2020). 
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Tobradex
®30 
Tobramycin 
and 
dexamethaso
ne 
ophthalmic 
suspension 
A suspension 
of topical 
antibiotic and 
corticosteroid 
Superficial 
bacterial 
ocular 
infection 
A and B 
Copaxone
®31  
Glatiramer 
acetate 
injection 
Polymeric 
mixture of 
peptide 
fragments in a 
pre-filled 
autoinjector 
Multiple 
sclerosis 
A and C 
Risperdal
® 
Consta®32 
Risperidone 
long acting 
injection 
Risperidone 
impregnated 
in microscale 
poly lactic-co-
glycolic acid 
microspheres 
Schizophrenia A and C 
Voltaren
® Gel33 
Diclofenac 
sodium 
topical gel 
Nonsteroidal 
anti-
inflammatory 
drug in topical 
formulation 
Osteoarthritis 
pain at joints 
amenable to 
topical 
treatment 
B 
 
 30. See Tobradex Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050818lbl.pdf (last 
accessed Apr. 18, 2020). 
 31. See Copaxone Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020622s102lbl.pdf 
(last accessed Apr. 18, 2020). 
 32. See Risperdal Consta Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021346_s31_s35_s
38_s39lbl.pdf (last accessed Apr. 18, 2020). 
 33. See Voltaren Gel Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/0221 
22s006lbl.pdf (last accessed Apr. 18, 2020); see also Certara’s Simcyp PBPK 
M&S Technology Achieves First FDA Virtual Bioequivalence Approval for 
‘Complex’ Generic Drug, CERTARA (June 12, 2019), 
https://www.certara.com/pressreleases/certaras-simcyp-pbpk-modeling-and-
simulation-technology-achieves-first-fda-virtual-bioequivalence-approval-for-
complex-generic-drug/?. 
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Epi-
Pen®34 
Epinephrine 
injection 
Epinephrine 
formulation in 
pre-filled 
autoinjector 
Emergency 
treatment of 
anaphylactic 
reactions 
C 
ProAir® 
HFA35 
Albuterol 
sulfate 
inhalation 
aerosol  
Albuterol 
sulfate in a 
metered dose 
inhaler 
Bronchospasm B and C 
Advair 
Diskus®36 
Fluticasone 
and 
salmeterol 
oral inhaler 
Mixture of a 
corticosteroid 
and beta2-
adrenergic 
bronchodilator 
in a metered 
dose inhaler 
Asthma, COPD A, B, and C 
NuvaRing
®37 
Etonogestrel 
and 
ethinyl 
estradiol 
vaginal ring 
Polymeric 
vaginal ring 
infused with 
hormones 
Contraceptive A, B, and C 
 
This Note suggests a more specific working definition for 
Complex Products, loosely based around the characteristics of 
Groups A, B, and C.38 
Lawmakers have focused on non-biological complex drug 
products because the generic-type pathway for follow-on drugs 
requires certain technical showings that are challenging for 
 
 34. See EPIPEN® Label, U.S. FOOD & DRUG ADMIN., U.S. FOOD & DRUG 
ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019430s053lbl.pdf 
(last accessed Apr. 18, 2020). 
 35. See ProAir HFA Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021457s036lbl.pdf 
(last accessed Apr. 18, 2020). 
 36. See Advair Diskus Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf 
(last accessed Apr. 18, 2020). 
 37. See NuvaRing Label, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021187s012lbl.pdf 
(last accessed Apr. 18, 2020). 
 38. See infra Section II. 
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Complex Products.39 In contrast, Complex Products that are 
regulated as devices and biologics allow follow-on competition to 
proceed via the more-flexible PMA or biosimilar pathways.40 
Although Complex Products are not synonymous with non-
biological products, this Note focuses on the drug-device 
distinction and unique challenges posed by non-biological 
Complex Products.41 
i. Non-Biological Complex Drugs (NBCDs) 
Non-Biological Complex Drugs (NBCDs) likely represent 
the most important subset of Complex Products, due to the 
unique regulatory challenges surrounding approval of complex 
generic equivalents.42 An industry-supported working group has 
described NBCDs as drugs in which the active substance is not 
a single, discrete molecular structure, but instead derives its 
activity from a particular mixture or nanoscale arrangement of 
components.43 In some cases, it may not be feasible to fully 
characterize or describe the active substance by present 
analytical methods and subtle variations can impart dramatic 
changes in functioning.44 Arguably, the defining aspect of 
NBCDs is that they “cannot be fully isolated, quantitated, 
characterized or described by physicochemical analytical 
means.”45 Moreover, the biological and therapeutic activity of 
NBCDs is often highly dependent on its manufacturing 
 
 39. See U.S. FOOD & DRUG ADMIN., supra note 7 (providing a rationale for 
its pre-ANDA program and enhanced pathway for Complex Products and 
providing a definition for combination products focused around drug and device 
features). 
 40. See infra Sections I(E)(ii) and I(E)(iii). 
 41. See infra Sections I(C) and II. 
 42. See Equivalence of Complex Drug Products, GENERICS AND 
BIOSIMILARS INITIATIVE (Apr. 14, 2017), http://www.gabionline.net/Non-
Biological-Complex-Drugs/Reports/Equivalence-of-complex-drug-products 
(summarizing that showing therapeutic equivalence of generic complex drugs 
has unique challenges). 
 43. See Shah, supra note 1 (stating NBCDs are an “active substance that is 
not homo-molecular but contains different (closely related, often nano-
particulate) structures”). 
 44. See Víctor R. Campos-García et al., Process Signatures in Glatiramer 
Acetate Synthesis: Structural and Functional Relationships, 7 SCIENTIFIC REP. 
12525, at 1–7 (Sept. 21, 2017), https://www.nature.com/articles/s41598-017-
12416-1 (showing that subtle changes in epitope abundance in glatiramer 
acetate results in substantial changes in therapeutic function); see also Shah, 
supra note 41. 
 45. Campos-García et al., supra note 44 at 1. 
2020] COMPLEX PRODUCTS 487 
 
process.46 NBCDs have been described as non-biologic products 
that have complexity approaching that of biological products.47 
NBCDs are a structurally and functionally diverse family of 
medical products, including: (1) polymeric micelles; (2) 
liposomes; (3) glatiramoids; (4) iron carbohydrate complexes; (5) 
drug nanocrystals; (6) low molecular weight heparins; and (7) 
albumin-bound drugs.48 For example, glatiramoids, such as 
Copaxone® and Glatopa®, comprise a mixture of polymer 
building blocks that self-assemble in the human body to form 
biologically active structures.49 Liposome-based drugs, such as 
Doxil®, involve tiny vesicles that encapsulate a potent 
therapeutic and carry it to a desired part of the human body.50 
As another example, Abraxane® involves nanocrystals of 
paclitaxel bound to albumin, a water-soluble globular protein 
obtained from human blood, which serves as a delivery vehicle 
for the chemotherapy agent.51 The FDA has created a working 
group dedicated to investigating regulatory challenges 
associated with NBCDs. 
ii. Complex Drug-Device Combinations 
The FDA does not necessarily deem combination products to 
be Complex Products, but certain “complex” drug-device 
combinations such as metered dose inhalers and injectors can 
 
 46. See Amneal Pharm. LLC v. FDA, 285 F. Supp. 3d 328, 337 (D.D.C. 2018) 
(stating that the FDA requires disclosure of “commercial-scale data” for “certain 
complex drug products and/or a complex manufacturing process”). 
 47. See Shah, supra note 1. 
 48. See Jon S. B. de Vlieger et al., Report of the AAPS Guidance Forum on 
the FDA Draft Guidance for Industry: “Drug Products, Including Biological 
Products, That Contain Nanomaterials”, 21 AAPS J. 55, 56 (2019), 
https://link.springer.com/content/pdf/10.1208/s12248-019-0329-7.pdf (providing 
an overview of the complex drug landscape). 
 49. See J. Y. Song et al., Glatiramer Acetate Persists at the Injection Site 
and Draining Lymph Nodes via Electrostatically-Induced Aggregation, 293 J. 
CONTROLLED RELEASE 36, 36–47 (2019). 
 50. See, e.g., Doxil, U.S. FOOD & DRUG ADMIN. 21 (2007), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf 
(“DOXIL is doxorubicin HCl encapsulated in long-circulating . . . liposomes. 
Liposomes are microscopic vesicles composed of a phospholipid bilayer that are 
capable of encapsulating active drugs.”). 
 51. See, e.g., Abraxane, U.S. FOOD & DRUG ADMIN. 1 (2013), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf 
(“ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles 
for injectable suspension) (albumin-bound)”). 
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fall within the category.52 Two examples, discussed above, are 
the Epi-Pen® epinephrine autoinjector and Advair® metered 
dose inhaler. 
Combination products seek to address classification 
challenges by using a primary mode of action (PMOA) inquiry to 
determine whether a given product will progress through the 
drug, device, or biologic framework. Yet, such an inquiry does 
not remedy the challenges associated with Complex Products, 
namely, where present scientific tools and understanding fail to 
furnish the information required to transit through the 
regulatory framework. Like the drug-device distinction, PMOA 
is determined predominantly by the presence of chemical action 
and thus chemical action serves as a regulatory gatekeeper even 
if the complex product is a combination product. For example, in 
the case of an inhaler containing a drug, the drug aspect would 
be deemed by the FDA Office of Combination Products to embody 
the PMOA while the device aspect would be deemed to serve a 
secondary function. However, if a hypothetical competitor 
wishes to make a generic inhaler, it is uncertain how similar the 
drug and device aspects must be to the referenced product. Most 
notably, even an apparently identical copy of a drug and device 
may nevertheless result in different bioavailability and 
therapeutic function. One reason for this difference is that 
complex drug-device combinations are susceptible to user 
interface and human factor effects. That is, the look, feel, and 
ergonomics of a device can affect how a person administers or 
accepts the drug, thus ultimately affecting therapeutic effect. 
The device may also affect the structural characteristics of a 
drug both before and after administration. These device-based 
effects can interplay with drug-based effects in unpredictable 
ways, resulting in complexity that makes regulatory approval 
uncertain and stymies follow-on competition. 
iii. Medical Nanotechnology and Nanodevices 
Complex Products also include medical products that 
involve nanotechnology, “nanodevices” (drug-like, molecular-
scale products that do not involve chemical action to achieve 
 
 52. See U.S. FOOD & DRUG ADMIN., GDUFA REAUTHORIZATION 
PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018-2022, at 25 (2016), 
https://www.fda.gov/media/101052/download (providing a definition for 
Complex Products that includes “metered dose inhalers” and “extended release 
injectables”). 
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their therapeutic result, e.g., gold nanoparticles), and other 
products for which existing classification or approval pathways 
pose a challenge.53 Whether the FDA will deem a given 
nanotechnology-based product to be a drug or a device is, again, 
determined by whether the intended effect involves “chemical 
action.”54 While products involving nanotechnology are not 
automatically assigned any special classification, the presence of 
nanotechnology can introduce sufficient complexity to render the 
FDA’s approval pathway uncertain. Nanotechnology-based 
products might thus meet the FDA’s definition of Complex 
Products.55 
The FDA has taken into account the advent of 
nanotechnology-based medicine in its regulatory framework.56 
Wisely, the FDA has determined that it will not issue general 
regulatory requirements or limitations on the use of 
 
 53. Id. 
 54. See Jordan Paradise, Reassessing Safety for Nanotechnology 
Combination Products: What Do Biosimilars Add to Regulatory Challenges for 
the FDA?, 56 ST. LOUIS U. L.J. 465, 495 (2012) (citing 21 U.S.C. § 321(h) (2006)) 
(“[T]he FDCA requires . . . that a device ‘does not achieve its primary intended 
purposes through chemical action . . . . ‘”). 
 55. See FDA’s Approach to Regulation of Nanotechnology Products, U.S. 
FOOD & DRUG ADMIN., https://www.fda.gov/science-research/nanotechnology-
programs-fda/fdas-approach-regulation-nanotechnology-products (last updated 
Mar. 23, 2018) (“[The] FDA has long encountered the combination of promise, 
risk, and uncertainty that accompanies emerging technologies. Nanotechnology 
is not unique in this regard.”); see also MARK DUVALL, FDA REGULATION OF 
NANOTECHNOLOGY 101 (2012) (“In light of the potential uncertainty 
surrounding the debate, it may be helpful for FDA to issue guidance on the 
subject [of nanotechnology-based devices].”). See generally Paradise, supra note 
50. 
 56. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: DRUG 
PRODUCTS, INCLUDING BIOLOGICAL PRODUCTS, THAT CONTAIN 
NANOMATERIALS (2017), https://www.fda.gov/media/109910/download 
(proposing, in a Draft Guidance document for comment purposes, a “risk-based” 
approach to products containing nano-technology). The document notes, among 
other things, that inclusion of nanotechnology “may result in product attributes 
that differ from those of products that do not contain such materials,” id. at 1, 
“nanomaterial carriers may exhibit inherent biological activity that is not 
related to the loaded active ingredient (e.g., immunogenicity) and could also 
affect the safety and effectiveness of the drug,” id. at 17, and “[a]ny critical 
structural change [by generics] in the multiple components of nanomaterial-
based products can influence the bioequivalence, pharmacology, and toxicology 
profiles, . . . [therefore] conventional [bioequivalence] studies alone may or may 
not be sufficient . . . ,” id. at 21. 
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nanotechnology in medicine.57 Still, nanoscale features can 
introduce new biological effects that are not otherwise present 
in the product and can serve to modulate existing biological 
effects.58 The FDA has further recognized that conventional 
analytical approaches to evaluating therapeutic products may 
not be sufficient when changes are made to nanotechnological 
features are altered or introduced.59 Such concerns parallel 
those of Complex Products generally. The medical products that 
the FDA regulates contain a variety of nanomaterials: for 
example, liposomes, micelles, specified nano-scale particle 
distributions, nanobubbles, nanocrystals, polymer-based 
therapeutics, and complex-based therapeutics—many of the 
same features which impart complexity to the products 
previously listed in Table 1. 60 Indeed, while nanomaterials are 
already commonly used in drugs,61 they can also be used in drug-
device combination products62 and non-drug products as well.63 
 
 57. The FDA has instead opted for a scientifically-guided risk-based 
approach. See generally id. 
 58. See id. at 5 (“[T]he interaction of nanomaterials with multiple plasma 
proteins . . . may endow nanomaterials with new biological properties.”). 
 59. Id. See also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
ASSESSING THE EFFECTS OF SIGNIFICANT MANUFACTURING PROCESS CHANGES, 
INCLUDING EMERGING TECHNOLOGIES, ON THE SAFETY AND REGULATORY 
STATUS OF FOOD INGREDIENTS AND FOOD CONTACT SUBSTANCES, INCLUDING 
FOOD INGREDIENTS THAT ARE COLOR ADDITIVES (2014), 
https://www.fda.gov/media/115075/download. 
 60. FDA provides guidance documents for products using nanomaterials in 
combination with drugs. See, e.g., U.S. FOOD & DRUG ADMIN., GUIDANCE FOR 
INDUSTRY: LIPOSOME DRUG PRODUCTS (2018), 
https://www.fda.gov/media/70837/download (providing guidelines for liposome-
containing drug product applications and recognizing the challenges for both 
ANDA and NDA applicants, particularly with respect to determining 
bioavailability); See generally Mary C. Till et al., Nanotech Meets the FDA: A 
Success Story About the First Nanoparticulate Drugs Approved by the FDA, 2 
NANOTECHNOLOGY L. & BUS. 163 (2005) (describing the first wave of nano-sized 
drugs that the FDA evaluated). 
 61. Jordan Paradise has provided a useful review and list of FDA-approved 
drugs that involve nanoscale features. See Paradise, supra note 54 at 518–19 
(providing a list of both FDA approved drugs and devices that involve 
nanotechnology). 
 62. See U.S. FOOD & DRUG ADMIN., supra note 60 at 10 (providing 
guidelines for liposome-containing drug product applications and recognizing 
the challenges for both ANDA and NDA applicants, particularly with respect to 
determining bioavailability). 
 63. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
CONSIDERING WHETHER AN FDA-REGULATED PRODUCT INVOLVES THE 
APPLICATION OF NANOTECHNOLOGY, at 6 (2014), 
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To determine if a product involves nanotechnology, the FDA 
considers whether the “product is engineered to have at least one 
external dimension, or an internal or surface structure, in the 
nanoscale range (approximately 1 nm to 100 nm)” and if the 
“product is engineered to exhibit properties. . . attributable to its 
dimension(s), even if these dimensions fall outside the nanoscale 
range, up to one micrometer (1,000 nm).” 64 Here, the FDA’s focus 
on “engineered” nanoscale features is an attempt to distinguish 
from conventionally-occurring and incidental nanoscale features 
from those that are intentionally imparted.65 
B. OVERVIEW OF FDA REGULATION OF MEDICAL PRODUCTS 
The FD&C Act imposes regulatory requirements on 
products intended for medical use.66 The FD&C Act requires 
that the safety and efficacy of all new drugs be evaluated and 
approved by the FDA prior to being introduced into interstate 
commerce.67 Since its promulgation in 1938, Congress has 
expanded the FDA’s regulatory authority to include additional 
classifications of medical products, notably medical devices68 
and drug-like biologics.69 
 
https://www.fda.gov/media/88423/download (providing two factors to consider 
in determining if the product involves nanotechnology which may suggest a 
need for additional risk assessment and stating “[n]anotechnology is an 
emerging technology that can be used in a broad array of FDA-regulated 
products, including . . . foods[,] . . . and cosmetics . . . .”). 
 64. Id. at 6. 
 65. Id. See U.S. FOOD & DRUG ADMIN., NANOTECHNOLOGY: A REPORT OF 
THE U.S. FOOD AND DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE 11 
(2007), https://www.fda.gov/media/74257/download (“In addition to other 
resources, the Task Force also considered the US Government-wide evaluation 
of Environmental, Health, and Safety Research Needs for Engineered 
Nanoscale Materials in developing this discussion and these 
recommendations.”). 
 66. See e.g., 21 U.S.C. §§ 331(a) (2011), 331(ll) (2011), 355(a) (2011), 360(k) 
(2012) (prohibiting introduction into interstate commerce of misbranded or 
unapproved drugs, devices, and biologics). 
 67. See 21 U.S.C. § 355(a) (2011) (“No person shall introduce or deliver for 
introduction into interstate commerce any new drug, unless an approval of an 
[NDA or ANDA] application. . . .”); Cf. U.S. FOOD & DRUG ADMIN., GUIDANCE 
FOR FDA STAFF AND INDUSTRY, MARKETED UNAPPROVED DRUGS – COMPLIANCE 
POLICY GUIDE, SEC. 440.100 MARKETED NEW DRUGS WITHOUT APPROVED 
NDAS OR ANDAS (2011), https://www.fda.gov/media/71004/download. 
 68. Medical Device Amendments of 1976, 21 U.S.C. § 301 (1976) (expressly 
delegating to FDA the authority to regulate medical devices). 
 69. The FDA’s authority to regulate biological products derives from both 
the Public Health Service Act (“PHS Act”) and the FD&C Act, which were 
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The FDA applies distinct regulatory schemes to medical 
products depending on whether it classifies the product as a 
drug,70 a device,71 a biologic,72 or a combination thereof.73 
Jurisdiction over each product is separately designated to 
different centers within the FDA.74 Generally, drugs are 
designated to the Center for Drug Evaluation and Research 
(CDER),75 devices to the Center for Devices and Radiologic 
Health (CDRH),76 and biologics to the Center for Biologics 
Evaluation and Research (CBER).77 Devices are further 
categorized as Class I, Class II, or Class III, based on the extent 
that safety and efficacy can be inferred due to the nature of the 
device.78 Combination products and other products that do not 
fall neatly into existing product classifications are evaluated by 
the Office of Combination Products (OCP) and designated to one 
 
subsequently amended and largely harmonized with drug regulations by the 
Food and Drug Administration Modernization Act of 1997 (“FDAMA”). See Food 
and Drug Administration Modernization Act of 1997, Pub. L. No. 105–115, 111 
Stat. 2296 (1997). Oversight over biologics, generally, extends back to the 
Biologics Control Act, which became effective in 1903. See also Pure Food and 
Drug Act of 1906, Pub. L. No. 59–384, 34 Stat. 768 (1906). 
 70. 21 U.S.C. § 201(g)(1) (2011) (defining a “drug”). 
 71. 21 U.S.C. § 201(h) (2011) (defining a “device”). 
 72. 42 U.S.C. § 262(i) (2011) (defining a “biologic”). 
 73. 21 C.F.R. § 3.2(e) (2010) (defining a “combination product”). 
 74. See RFD Jurisdictional Decisions, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/combination-products/jurisdictional-information/rfd-
jurisdictional-decisions (last updated Feb. 16, 2018). 
 75. See Capsular Decisions—Products Assigned to CDER, U.S. FOOD & 
DRUG ADMIN., https://www.fda.gov/combination-products/rfd-jurisdictional-
decisions/capsular-decisions-products-assigned-cder (last updated Feb. 16, 
2018). 
 76. See Capsular Decisions, supra note 71. 
 77. See id., many notable exceptions to jurisdiction apply and centers 
cooperate and share their expertise where appropriate. See e.g., Transfer of 
Therapeutic Biological Products to the Center for Drug Evaluation and 
Research, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/combination-
products/jurisdictional-information/transfer-therapeutic-biological-products-
center-drug-evaluation-and-research (last updated Feb. 16, 2018) (transferring 
jurisdiction of therapeutic monoclonal antibodies, immunomodulators, and 
growth factors from CBER to CDER); see also Intercenter Agreement Between 
the Center for Biologics Evaluation and Research and the Center for Devices and 
Radiological Health, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/combination-products/jurisdictional-
information/intercenter-agreement-between-center-biologics-evaluation-and-
research-and-center-devices-and (last updated Feb. 16, 2018) (transferring 
jurisdiction of in vitro blood diagnostics to CBER from CDRH). 
 78. 21 U.S.C. § 360c (2012). 
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of the centers, i.e., CDER, CDRH, or CBER, which have primary 
jurisdiction for premarket review and regulatory life of the 
product.79 
C. CLASSIFICATION OF MEDICAL PRODUCTS 
i. Is it a Drug, Device, or Biologic? 
Product classification determines the structure of the FDA’s 
premarket review and regulatory pathways for follow-on 
competition. The scope and burden of premarket review varies 
enormously between product classifications: drug pre-clinical 
investigations, clinical trials, and regulatory approval take an 
average of twelve years and over $350 million80 while the most 
burdensome form of device clinical investigation and approval 
averages 4.5 years and $75 million.81 Further, for medical 
products that make it to market, the strength and duration of 
regulatory exclusivity differs based on the product’s 
classification.82 
The FD&C Act defines drugs to include “articles intended 
for use in the diagnosis, cure, mitigation, treatment, or 
prevention of disease in man or other animals” and “articles 
(other than food) intended to affect the structure or any function 
of the body of man or other animals” as well as articles listed in 
certain pharmacopeial compendia and components of any of the 
same.83 
 
 79. See Jurisdictional Information, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/combination-products/classification-and-jurisdictional-
information (last updated Apr. 9, 2020). 
 80. Matthew Herper, The Cost of Creating a New Drug Now $5 Billion, 
Pushing Big Pharma to Change, FORBES PHARMA & HEALTHCARE (Aug. 11, 
2013), https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-
staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-
medicine/#7753cc096bfc. 
 81. Brian Buntz, FDA Planning Faster PMA Pathway for Some Products, 
MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY (Jan. 31, 2014), 
https://www.mddionline.com/fda-planning-faster-pma-pathway-some-products. 
 82. See e.g., 21 C.F.R. §§ 314.108 (2012), 316.31 (2011), & 316.34 (2004); see 
also FD&C Act, 21 U.S.C 9 §§ 505A, 505E, & 505(j)(5)(B)(iv) (2012) (providing 
various regulatory extensions). Compare 21 U.S.C. § 355(b) (2011), and 21 
U.S.C. § 360(k) (2012), with 42 USC § 262(l) (2011) (providing the ANDA process 
for a generic drug, 510(k) process for a substantially equivalent device, and 
process for a biosimilar). 
 83. 21 U.S.C. § 321(g)(1) (2011) (defining a “drug”). 
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Within the FD&C Act, devices are defined as a subset of 
article, specifically “an instrument, apparatus, implement, 
machine, contrivance, implant, in vitro reagent, or other similar 
or related article.”84 The statutory definition of a device is 
further categorized according to intended use, similar to that for 
a drug, but with an important limitation. Mirroring the 
language used to define drugs, the FD&C Act defines devices as 
“intended for use in the diagnosis of disease or other conditions, 
or in the cure, mitigation, treatment, or prevention of disease, in 
man or other animals,” or “intended to affect the structure or any 
function of the body of man or other animals . . . .”85 However, in 
the FD&C Act, Congress expressly required that a device “not 
achieve its primary intended purposes through chemical action 
within or on the body of man or other animals and which is not 
dependent upon being metabolized for the achievement of its 
primary intended purposes . . . .”86 
In the FD & C Act, a product is classified as a biologic if it 
is: 
[A] virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood 
component or derivative, allergenic product, protein (except any 
chemically synthesized polypeptide), or analogous product, or 
arsphenamine or derivative of arsphenamine (or any other trivalent 
organic arsenic compound), applicable to the prevention, treatment, or 
cure of a disease or condition of human beings.87 
That is, biologics are defined by origin, while drugs and 
devices are defined by intended use. 
Although the FDA relies on these statutory definitions to 
determine how to classify a given product, the agency has 
historically interpreted these definitions broadly so as to 
preserve its authority to regulate.88 For example, the FDA 
 
 84. 21 U.S.C. § 321(h) (2011) (defining a “device”). 
 85. Id. 
 86. Id. 
 87. 42 U.S.C. § 262(i) (2011) (defining a “biologic”). 
 88. See United States v. Bacto-Unidisk, 394 U.S. 784, 800 (1969) (deferring 
to the FDA’s authority to interpret an antibiotic diagnostic apparatus as a drug 
rather than a device). Even after subsequent amendments provided express 
distinctions between drugs and devices, the FDA retained its willingness to use 
discretion to classify a product according to the interest of the public health. See 
U.S. FOOD & DRUG ADMIN., CLASSIFICATION OF PRODUCTS AS DRUGS AND 
DEVICES AND ADDITIONAL PRODUCT CLASSIFICATION ISSUES (2017), 
https://www.fda.gov/media/80384/download. However, at least one district 
court has suggested that the FDA’s position is not tenable. See Bracco 
Diagnostics Inc v. Shalala, 963 F. Supp. 20, 28, 31 (D.D.C. 1997). 
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presently considers that, conceptually, all medical products 
meet the definition of a drug.89 Indeed, the definition of a device 
can be interpreted as defining a subset of the drug definition; 
specifically, a subset having the limitation that they do not 
achieve their primary intended purposes via chemical action, or 
metabolism, within or on the body.90 The genera of products 
listed in the biologics definition can be likewise interpreted as 
another subset of drugs.91 Products that meet the definition of 
both a drug and a biologic are classified as a biologic, while 
products that meet the definition of both a drug and a device are 
classified as a device.92 Whether a product is a device rather than 
a drug or biologic will hinge on whether the product achieves its 
primary intended purposes through “chemical action” within or 
on the body.93 Because neither drugs nor biologics include food, 
the provision that devices exclude products that achieve their 
purpose through metabolism has not been a meaningful 
distinction.94 
 
 
 
 
 
 
 
 
 89. See U.S. FOOD & DRUG ADMIN., supra note 88. 
 90. Congress chose to expressly remove a provision of the FD&C Act that 
excluded devices from being drugs. See Safe Medical Devices Act of 1990, Pub. 
L. No. 102-629, § 14, 104 Stat. 4511, 4524–25. Still, while still standing safely 
outside the rabbit hole of FD&C definitions, it is worth acknowledging that 
interpreting all medical products to be drugs invites some absurd consequences. 
At the very least, it seems reasonable to expect that products meeting the 
definition as device should be permitted passage through the regulatory domain 
while classified as devices. See, Genus Med. Tech. v. United States Food & Drug 
Admin., Civil Action No. 19-544 (JEB), 2019 U.S. Dist. LEXIS 210397 * 2019 
WL 6683777. 
 91. See U.S. FOOD & DRUG ADMIN., supra note 88; see also Biologics Price 
Competition and Innovation Act of 2009, S. 1695, 100th Cong. § 7002(e) (2007). 
See also U.S. FOOD & DRUG ADMIN., INTERPRETATION OF THE “DEEMED TO BE A 
LICENSE” PROVISION OF THE BIOLOGICS PRICE COMPETITION AND INNOVATION 
ACT OF 2009 (2018), https://www.fda.gov/media/119272/download. 
 92. See U.S. FOOD & DRUG ADMIN., supra note 91. 
 93. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical 
action). 
 94. See id. (explaining the FDA’s current thinking on chemical action). 
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Table 2. Example Classification of Medical Products 
Medical Product Classification 
An artificial hip implant Device 
Beta blockers, which interact with 
beta receptors and block access to the 
receptor 
Drug 
A recombinant human granulocyte 
colony stimulating factor Biologic 
An autoinjector configured to provide 
metered doses of a synthetic myelin 
protein 
Combination 
A complex mixture of polymers that 
assemble into a variety of structural 
forms that serve to attenuate an 
immune response in the human body Examples of Complex Products. 
 
Classification is based on 
whether the primary intended 
purpose is through “chemical 
action” within or on the body. 
A liposome containing a collection of 
non-biological molecular components, 
including a sensor, a cytotoxin, and a 
molecular switch configured to 
jettison the cytotoxin upon stimulus 
of the sensor 
A synthetic tissue embedded with 
biologically active components 
 
Applicants often seek to have their products classified as a 
device rather than a drug or biologic due to the less burdensome 
premarket review process afforded to devices.95 Unexpected 
classification of a device as a drug can preclude further 
development of that product.96 The Office of Combination 
 
 95. Id. See also Letter from Jill Hartzel Warner, Assoc. Comm’r for Special 
Medical Programs, Food and Drug Admin., to Jeffrey N. Gibbs and Anne K. 
Walsh, Attorneys for Prevor (Jan. 13, 2015) (on file with Food and Drug 
Administration); Letter from Suzanne O’Shea, Product Jurisdiction Officer, 
Food and Drug Admin., to LuAnn Erlich, Senior Dir. of Pharm. and Comput. 
Services, Apotex Corp. (Sept. 8, 2003) (on file with Food and Drug 
Administration). 
 96. See Bracco Diagnostics Inc v. Shalala, 963 F. Supp. 20, 28–32 
(explaining that small device companies might not be able to afford to bring a 
drug to market). Sometimes extensive the consequences of classification justify 
repeated and presumably expensive litigation. Cf. Prevor v. FDA, 895 F. Supp. 
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Products (OCP) handles the FDA’s classification and jurisdiction 
assignments.97 Those pursuing regulatory review can submit 
informal inquiries or formal Requests for Designation (RFDs) to 
classify the product and identify the center having jurisdiction. 
ii. Chemical Action 
The FDA recently issued guidance98 regarding how it 
applies “chemical action” to distinguish drugs and biologics from 
devices.99 Specifically, the FDA has defined chemical action as 
follows: “a product exhibits ‘chemical action’ if it interacts at the 
molecular level with bodily components (e.g., cells or tissues) to 
mediate (including promoting or inhibiting) a bodily response, or 
with foreign entities (e.g., organisms or chemicals) so as to alter 
that entity’s interaction with the body.”100 
Perhaps recognizing the futility of defining “chemical 
action” as interactions “at the molecular level,” the FDA has 
further provided that: 
For purposes of this interpretation, an interaction at the 
molecular level occurs through either chemical reaction (i.e., 
formation or breaking of covalent or ionic bonds), intermolecular 
forces (e.g., electrostatic interactions), or both. The mere 
exchange of non-chemical energy (e.g., electromagnetic or 
thermal energy between a product and the body would not 
constitute “chemical action.”101 
 
2d 90 (D.D.C. 2012); Prevor v. U.S. Food & Drug Admin., 67 F. Supp. 3d 125 
(D.D.C. 2014). 
 97. See Combination Products, Jurisdictional Information, U.S. FOOD & 
DRUG ADMIN., https://www.fda.gov/combination-products/classification-and-
jurisdictional-information (last accessed Apr. 9, 2020). 
 98. The FDA publishes its current thinking on various topics by way of 
guidance documents. While guidance documents do not have the force of law 
and are not binding, they have proven to be an effective means of regulating 
industry and developing policy. See Guidances, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/industry/fda-basics-industry/guidances (last updated May 
24, 2018) (summarizing the FDA’s use of guidance documents). 
 99. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical action 
and explaining the FDAs current thinking on the same). 
 100. Id. at 7. For a more reasoned take on chemical action, see, e.g., W.J. 
Koolage & R. Hall, Chemical Action: What Is It, and Why Does It Really Matter?, 
13 J. NANOPARTICLE RES. 1401, 1401–17 (2011); see also FDA Finalizes Product 
Classification Guidance, HYMAN, PHELPS & MCNAMARA PC: FDA L. BLOG (Oct. 
3, 2017), http://www.fdalawblog.net/2017/10/fda-finalizes-product-
classification-guidance/; Drug or Device?— FDA Provides More Clarity—or Does 
It?, CAMARGO PHARMA: CAMARGO BLOG. 
 101. U.S. FOOD & DRUG ADMIN., supra note 88, n. 12. 
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This is, again, somewhat circular: “chemical action” is 
defined as interactions on the “molecular” level, which are 
interactions that include “chemical” reactions. However, recent 
guidance provides at least one bright line rule: chemical action 
is not mere transfer of electromagnetic or thermal energy.102 
Pacemakers, electrocauteries, cryotherapy, and 
neurostimulation devices are thus firmly on the device side. The 
FDA has provided several examples to illustrate products that 
do, and do not, achieve their primary purpose through chemical 
action. 
 
Table 3. Examples of Medical Products that Illustrate Chemical 
Action.103 
Medical Product 
Does this product achieve 
its primary intended purpose 
through “chemical action”? 
Inert synthetic polymers used 
to reduce post-operative 
tissue adhesions 
No 
Acrylate polymer bone filler No 
Topical surgical adhesive No 
Gold nanoparticles that 
absorb electromagnetic 
radiation and radiate thermal 
energy damaging nearby 
tissue and killing cancer cells 
No 
Liquid nitrogen gas used to 
treat warts 
No 
Hydroxocobalamin, which 
binds to cyanide to act as an 
antidote 
Yes 
Polymyxin B sulfate, a 
cationic surfactant that is 
attracted to and 
electrostatically adheres to 
the bacterial membrane, 
lysing and killing the bacteria 
Yes 
 
 102. Id. 
 103. Id. 
2020] COMPLEX PRODUCTS 499 
 
Magnesium sulfate for 
treating magnesium 
deficiency 
Yes 
Beta blockers, which interact 
with beta receptors and block 
access to the receptor 
Yes 
 
Lastly, the FDA has clarified that the concept of chemical 
action relates to the “primary intended purposes” of the device 
“as a whole” and thus does not hinge on whether the product 
involves any chemical action at all.104 Further, as noted above, 
the FDA considers devices to be a subset of drugs, rather than 
being a mutually exclusive category. Thus, while a device can be 
said to work by means other than chemical action or metabolic 
action, the definition for drugs is not restricted with respect to 
mode of action.105 
D. CLASSIFICATION OF COMBINATION PRODUCTS 
i. Combination Products 
When a product comprises two or more separately classified 
components, i.e., a mixed pairing of drug, device, or biologic 
components, the FDA classifies the product as a combination 
product.106 Combination products thus correspond to 
drug/device, biologic/device, drug/biologic, or 
drug/device/biologic component mixtures. The Federal Code 
defines combination products as a product comprising two or 
more regulated components: 
(1) . . . that are physically, chemically, or otherwise combined or mixed 
and produced as a single entity; 
(2) . . . packaged together in a single package or . . . ; 
(3) . . . packaged separately . . . intended for use only with an approved 
individually specified drug, device, or biological product where both are 
required to achieve the intended use . . . ; or 
 
 104. Id. 
 105. The FDA’s approach may be challenged by a recent district court 
decision in Genus Medical Technologies, which may force the FDA to reconsider 
whether at least a contrast agent can be regulated as a drug if it lacks chemical 
action, particularly in light of other contrast agents being regulated as devices. 
See Genus Medical Tech. v U.S. Food and Drug Admin., Civil Action No. 19-544 
(JEB), 2019 U.S. Dist. LEXIS 210397 * | 2019 WL 6683777. Note, also, that 
drugs exclude food. See 21 U.S.C. § 321(g)(a) (2011). 
 106. 21 C.F.R. § 3.2(e) (2005) (defining combination products). 
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(4) . . . packaged separately . . . for use only with another individually 
specified . . . drug, device, or biological product where both are required 
to achieve the intended use.107 
Combination products are important in the context of 
Complex Products since the FDA expressly enumerated complex 
drug-device combinations as an example of Complex Products. 
ii. Primary Mode of Action 
To determine how any given combination product should be 
regulated, the FDA first determines the PMOA of the product.108 
Specifically, the FDA will identify the single mode of action that 
it expects makes the greatest contribution to the overall 
intended therapeutic effect of the product.109 The FDA looks to 
determine the “means” by which the product achieves its 
intended therapeutic effect. Typically, combination products 
exhibit multiple modes of action.110 Unintuitively, this means 
that PMOA is based on the action intended, not necessarily the 
action that occurs. 
Once the PMOA has been identified, the product is classified 
based on whether the PMOA corresponds to “[t]he actions 
provided by a biological product, a device, and a drug.”111 A 
combination product is classified as a biologic if its PMOA “acts 
by means of” a product defined as a biologic.112 The combination 
product is a device if its PMOA acts by means of a device, but 
not if it acts by means of a biological product, or through 
chemical action within or on the body, or if it is dependent upon 
being metabolized. Lastly, drug classification is a catch all: the 
combination product is a drug if it has a PMOA that does not 
meet either of their two definitions.113 When looking at device-
 
 107. Id. 
 108. 21 U.S.C. § 353(g)(d) (2016). 
 109. 21 U.S.C. § 353(g)(c) (2016). 
 110. 21 C.F.R. § 3.2(k) (2005). 
 111. 21 C.F.R. § 3.2(k) (2005). 
 112. 21 C.F.R. § 3.2(k) (2005). See also 21 U.S.C. § 351(i) (2017) (listing 
products that are deemed biologics). 
 113. Of course, drugs, devices, and biologics do not necessarily function 
according to generalized modes of action. Ideally, the FDA prefers to think of 
itself as taking a science-based, product-specific approach to regulation, but 
Congress has expressly set forth a distinction between drugs, devices, and 
biologics. PMOA is simply an unavoidably blunt tool for separating products 
into the product categories devised by Congress without any particular 
scientific basis. 
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drug combination products, classification ultimately depends, 
again, on the FDA’s interpretation of chemical action. 
It is worth noting that such classification is merely for 
determining primary jurisdiction over the product. Even if the 
FDA assigns a drug-device combination product to CDRH, 
constituent parts of the product will still be regulated as needed 
to assure safety and efficacy.114 That is, due to the broad 
regulatory power vested in the FDA, it can later regulate such 
products as it deems necessary and, in any event, the FDA will 
maintain quality control requirements of the non-primary 
components.115 Nonetheless, the PMOA determination and the 
resulting combination product classification has significant 
consequences due to the differing regulatory burdens between 
drugs, devices, and biologics.116 Indeed, the differing PMOA-
based determination of product classification has led to some 
unintuitive and seemingly unfair outcomes.117 Recognizing that 
this is an area of uncertainty for applicants, the Office of 
Combination Products encourages applicants to submit an 
informal inquiry or a Request for Determination (RfD) prior to 
seeking premarket review of products for which classification is 
uncertain.118 Applicants can further appeal such determinations 
by way of a Request for Reconsideration.119 
 
 114. See U.S. Food & Drug Admin., GUIDANCE FOR INDUSTRY AND FDA 
STAFF: CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS FOR 
COMBINATION PRODUCTS (2015), https://www.fda.gov/media/90425/download 
(“The constituent parts of a combination product retain their regulatory status 
(as a drug or device, for example) after they are combined.”). 
 115. Id. 
 116. See Genus Med. Tech. v. United States Food & Drug Admin., No. 19-
544 (JEB), 2019 U.S. Dist. LEXIS 210397 * 2019 WL 6683777 (indicating that 
if a particular contrast agent were classified as a device it could obtain approval 
for about $60,000, whereas obtaining drug approval would be “over half a 
million dollars in addition to a continuing annual cost north of $186,000.”). 
 117. Response to Request for Designation from U.S. Food & Drug Admin., to 
AWBAT Plus Wound Dressing (Dec. 3, 2009). 
 118. See Jurisdictional Information, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/combination-products/classification-and-jurisdictional-
information (last updated Apr. 9, 2020). 
 119. Id. 
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E. BARRIERS TO MARKET ENTRY 
i. Drugs 
To market a new drug in the U.S., an innovator must submit 
a new drug application (NDA) to the FDA demonstrating that 
the drug is safe and effective for its intended use, and seek to 
obtain the FDA’s express approval.120 For new drugs, applicants 
can proceed through the premarket review process via either a 
505(b)(1) NDA or a 505(b)(2) NDA (a type of “paper” NDA).121 In 
either case, the NDA is intended to be a complete, candid, and 
authoritative report of an applicant’s relevant knowledge arising 
from scientific and clinical investigations of the drug.122 
A 505(b)(1) NDA requires that applicants conduct and 
report the results of their own well-controlled clinical studies 
evaluating safety and efficacy.123 These clinical studies typically 
take the form of Phase 0, Phase 1, Phase 2, and Phase 3 trials.124 
The NDA must also include a complete description of the drug, 
all components, its method of manufacture, its manufacturing 
facility and controls, specimens of the drug, and proposed 
labeling.125 Drugs are deemed to be a new molecular entity 
(NME) if the structure of one of the active ingredients (i.e., 
“active moiety”) does not correspond to a previously approved 
structure, or esters, salts, clathrate, and other noncovalent 
derivatives thereof.126 Whether a drug is an NME is factor that 
 
 120. See 21 U.S.C. § 355(a) (2011). 
 121. See 21 U.S.C. § 355(b) (2011). 
 122. See 21 U.S.C. § 355(b)(1)(A) (2011). For example, the clinical studies 
should have objective end points that are clinically relevant to the intended use, 
should conform with good clinical practice, and should be conducted and 
reported in a manner such that they are scientifically credible. 
 123. See 21 U.S.C. § 355(i)(2)(A) (2011). 
 124. Id. 
 125. See 21 U.S.C. § 355(b)(1)(B-F) (2011). 
 126. The FDA uses the NME designation for internal administration and 
regulatory research purposes. Still, the classification is important because it 
may guide internal policy and decision making. See U.S. FOOD & DRUG ADMIN., 
OFFICE OF PHARMACEUTICAL QUALITY, POLICY AND PROCEDURES: NDA 
CLASSIFICATION CODES (2015), https://www.fda.gov/media/94381/download 
(summarizing the various ways CDER classifies NDA products). See also 21 
C.F.R. § 314.3 (2016) (“Active moiety is the molecule or ion, excluding those 
appended portions of the molecule that cause the drug to be an ester, salt 
(including a salt with hydrogen or coordination bonds), or other noncovalent 
derivative (such as a complex, chelate, or clathrate) of the molecule, responsible 
for the physiological or pharmacological action of the drug substance.”). The 
FDA uses NCE, which relates to a five-year market exclusivity incentive for 
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the FDA weighs when considering investigation new drug (IND) 
applications,127 risk evaluation and mitigation strategies 
(REMS) submissions, 128 and its evaluation of NDAs.129 
In contrast with the 505(b)(1) process, a 505(b)(2) NDA can 
reference a prior finding by the FDA of the same drug’s safety 
and efficacy, published clinical data, or prior clinical 
investigations conducted for someone other than applicant but 
for which the applicant does not have right of reference.130 In a 
505(b)(2) NDA, the applicant need only provide additional 
clinical or scientific information in connection with the 
difference between the new drug product and the prior approved 
drug.131 A 505(b)(2) NDA is commonly used to pursue a new use, 
indication, formulation, dosage, route of administration, 
prodrug, or to label a previously approved drug.132 However, a 
505(b)(2) NDA should not be used as a substitute entry point for 
generic products that are below the bioequivalence requirements 
of the 505(j) abbreviated new drug application (ANDA) 
pathway.133 
In considering whether to approve a new drug, the FDA 
conducts a risk-benefit analysis that considers the applicant’s 
 
bringing such products to market. See 21 C.F.R. § 314.108 (2012) (“New 
chemical entity means a drug that contains no active moiety that has been 
approved by FDA in any other NDA submitted under section 505(b) of the 
Federal Food, Drug, and Cosmetic Act.”). See also U.S. FOOD & DRUG ADMIN., 
GUIDANCE FOR INDUSTRY: NEW CHEMICAL ENTITY EXCLUSIVITY 
DETERMINATIONS FOR CERTAIN FIXED-COMBINATION DRUG PRODUCTS (2014), 
https://www.fda.gov/media/87932/download (indicating that the NCE incentive 
is determined based off of each drug substance, so mixtures of old and new APIs 
can qualify for the NCE incentive). 
 127. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND REVIEW 
STAFF: BEST PRACTICES FOR COMMUNICATION BETWEEN IND SPONSORS AND 
FDA DURING DRUG DEVELOPMENT (2017), 
https://www.fda.gov/media/94850/download (urging pre-IND meetings for 
sponsors of NME INDs). 
 128. See 21 U.S.C. § 355-1 (2011). 
 129. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE 
GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 (2012), 
https://www.fda.gov/media/82022/download (setting forth a program for 
improving transparency and communication surrounding NME NDAs). 
 130. U.S. FOOD & DRUG ADMIN., GUIDANCE OF INDUSTRY: APPLICATIONS 
COVERED BY 505(b)(2) (1999), https://www.fda.gov/media/72419/download. 
 131. Id. 
 132. Id. 
 133. In other words, if the product to be approved is identical or generic to a 
prior approved product, then it must be equal or better to be suitable for the 
505(b)(2) pathway. Id. 
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clinical data, currently-available alternative treatments, and 
whether the risks can be addressed by risk management and 
mitigation strategies (REMS).134 Refusal is typically on the basis 
that the NDA fails to sufficiently establish that the drug is safe 
and effective under the conditions set forth in the proposed 
labeling.135 However, applications can also be refused on various 
other grounds, including failure to list patents for submission to 
the Orange Book, inadequate manufacturing controls, or the 
FDA’s determination that a proposed label is false or 
misleading.136 The NDA review and approval process is highly 
technical and product-specific.137 To assist applicants and in the 
interest of transparency, the FDA provides product-specific and 
general guidances.138 The CDER further provides a directory 
listing many of its internal policies and procedures with respect 
to NDA approval.139 
Generic drug makers can seek approval of follow-on 
products by way of an ANDA, i.e., a 505(j), or by way of the 
505(b)(2) approval process discussed above.140 The ANDA 
process requires the applicant to show that the follow-on product 
is bioequivalent, and has the same active ingredient, route of 
administration, dosage form, and strength as a previously-
approved reference product.141 21 C.F.R. § 314.3 defines 
bioequivalence, active ingredient, dosage form, and strength. 
 
 134. See Drugs: Development and Approval Process, U.S. FOOD & DRUG 
ADMIN., https://www.fda.gov/drugs/development-approval-process-drugs (last 
updated Oct. 28, 2019) (explaining the FDA’s risk-benefit approach to drug 
approval). 
 135. See 21 U.S.C. §§ 355(c)-(d) (2011) (setting forth approval, refusal, and 
rationales for the same). 
 136. See 21 U.S.C. § 355(d) (2011). 
 137. See, e.g., U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
PRUSSIAN BLUE DRUG PRODUCTS—SUBMITTING A NEW DRUG APPLICATION 
(2003), https://www.fda.gov/media/71071/download (providing guidance for a 
particular class of products); see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR 
INDUSTRY: BIOAVAILABILITY STUDIES SUBMITTED IN NDAS OR INDS—GENERAL 
CONSIDERATIONS (2019), https://www.fda.gov/media/121311/download 
(providing general guidance for how to best meet bioavailability requirement 
for NDA applications set forth in 21 C.F.R. § 320). 
 138. Id. 
 139. CDER Manual of Policies & Procedures (MAPP), U.S. FOOD & DRUG 
ADMIN., https://www.fda.gov/about-fda/center-drug-evaluation-and-research-
cder/cder-manual-policies-procedures-mapp (last updated Apr. 17, 2020) 
(providing a searchable directory of its published policies and procedures). 
 140. See 21 U.S.C. § 355(b)(1) (2011); see also 21 U.S.C. § 355(j) (2011). 
 141. See 21 U.S.C. § 355(j) (2011). 
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The sameness of the active ingredient, i.e., drug substance, is 
established by showing that the follow-on active has the same 
chemical structure as the reference product.142 Bioequivalence is 
typically shown by demonstrating an absence of significant 
difference in bioavailability, which is the rate and extent to 
which the active ingredient is absorbed into the bloodstream and 
made available to the target treatment site.143 Alternative 
approaches to showing bioequivalence exist but applicants often 
do not have certainty regarding what approaches the FDA will 
deem suitable,144 particularly for products that have not yet seen 
generic entry. 
As required by the Hatch-Waxman Act, the FDA publishes 
a list of all approved NDA drugs in a compendium called the 
Orange Book, together with a list of patents supplied by each 
drug’s sponsor.145 Before any generic drug can be approved by 
the FDA, whether under 505(j) or 505(b)(2), a generic drug 
maker must first certify that marketing its generic drug would 
not infringe any valid, listed patents.146 In this manner, the 
regulatory approval process for generic drugs involves use of the 
U.S. patent system, a separately regulatory regime, to act as a 
secondary gatekeeper for generic approval. 
ii. Devices 
a. Class I, Class II, and Class III 
The FD&C Act provides for a risk-based approach to device 
regulation.147 Once a product is recognized as a device, CDRH 
further classifies the device as Class I, Class II, or Class III, 
 
 142. See 21 U.S.C. § 320 (2012). 
 143. See 21 U.S.C. § 314.3 (2012); see also 21 U.S.C. § 320 (2012). 
 144. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
BIOEQUIVALENCE RECOMMENDATIONS FOR SPECIFIC PRODUCTS (2012), 
https://www.fda.gov/media/71401/download (explaining FDA’s process for 
conveying its bioequivalence expectations, which can be product specific and 
deviate from general guidance). 
 145. See 21 U.S.C. § 355(b)(1) (2011); see also 21 C.F.R. § 314 (2012). 
 146. See 21 U.S.C. § 355(b)(2)(A) (2011); see also 21 U.S.C. § 355(j)(2)(vii) 
(2011). 
 147. See 21 U.S.C. § 360c(a) (2011); see also U.S. FOOD & DRUG ADMIN., 
GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF: FDA 
AND INDUSTRY PROCEDURES FOR § 513(G) REQUESTS FOR INFORMATION UNDER 
THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (2012), 
https://www.fda.gov/media/78456/download (summarizing the FDA’s device 
classification scheme). 
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corresponding to what controls are warranted to assure safety 
and efficacy.148 Class I devices are regulated by general controls 
applicable to all devices.149 Class II devices are those that can be 
sufficiently regulated by way of incorporating additional special 
controls, but for which general controls are not themselves 
sufficient to assure safety and efficacy.150 Class III devices are 
typically devices that support or sustain human life and require 
premarket approval due to greater risk of harm.151 The FDA 
provides a searchable online database listing the device 
classifications and the Federal Code is regularly updated with 
classification details.152 A Section 513(g) request can be 
submitted to the FDA to inquire what class a device falls within; 
whether a PMA, 510(k), or neither, would be required before 
bringing the product to market; and if any special requirements 
or guidances apply to such product types.153 A device is 
automatically assigned to Class III unless it is a type of device 
already categorized by the FDA as Class I or Class II and the 
 
 148. See U.S. FOOD & DRUG ADMIN., supra note 147. 
 149. The FDA describes general controls as statutory requirements 
authorized by FD&C Act. For example, general controls include the 
adulteration and misbranding provisions, the premarket review processes, the 
requirements to register drug and device producers, statutorily banned devices, 
recall provisions, adverse event reporting, product tracking systems, 
inspections, GMP requirements, public notices, and other notices. See 
Regulatory Controls, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medical-
devices/overview-device-regulation/regulatory-controls (last updated Mar. 27, 
2018) (defining general controls and listing examples). 
 150. Special controls are described as regulatory requirements not 
applicable to all devices and typically product specific, e.g., performance 
standards, postmarket surveillance, patient registries, black box warnings and 
other special labeling requirements, premarket data requirements, and 
compliance with guidelines. See Regulatory Controls, U.S. FOOD & DRUG 
ADMIN., https://www.fda.gov/medical-devices/overview-device-
regulation/regulatory-controls (last updated Mar. 27, 2018) (defining special 
controls and listing examples). 
 151. Id. 
 152. See Product Code Classification Database, U.S. FOOD & DRUG ADMIN. 
(2019), 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm; see 
also 21 C.F.R. §§ 862–892 (2012) (listing virtually all medical device types along 
with their classifications, product codes, and FDA premarket review 
organizations). 
 153. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD 
AND DRUG ADMINISTRATION STAFF: FDA AND INDUSTRY PROCEDURES FOR 
SECTION 513(G) REQUESTS FOR INFORMATION UNDER THE FEDERAL FOOD, 
DRUG, AND COSMETIC ACT (2012), https://www.fda.gov/media/78456/download 
(summarizing the FDA’s current thinking on the 513(g) process). 
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device is substantially equivalent to another device already on 
the market as determined by a 510(k) submission.154 In response 
to, or as an alternative to, the default classification of new 
devices into Class III, a device manufacturer can submit a De 
Novo Classification Request.155 In response, the FDA conducts a 
risk-based evaluation of the device and assigns it to Class I or 
Class II if general and special controls are sufficient to provide 
reasonable assurance of safety and efficacy.156 
b. Exempt Devices, 510(k), and Premarket Approval 
Almost all Class I devices and some Class II devices are 
exempted from the requirement to obtain premarket approval or 
provide the FDA with premarket notification.157 Some Class I 
devices are further exempted from satisfying GMP general 
requirements, provided records and complaint files are kept, and 
the device is not labeled as sterile when it is sold.158 The FDA 
provides an online database of all exempt devices.159 
The FDA requires premarket notification by way of a 510(k) 
submission at least 90 days before a device is marketed in the 
U.S. for the first time, or before a device already marketed is 
modified in a manner which may significantly affect safety or 
effectiveness.160 In some cases, changes to a product’s packaging 
or label can require submission of a 510(k).161 This notification 
requirement applies to every Class I, Class II, and Class III 
medical device unless it is exempt or engaged in the separate 
 
 154. 21 U.S.C. § 513(f) (2019). 
 155. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD 
AND DRUG ADMINISTRATION STAFF: DE NOVO CLASSIFICATION PROCESS 
(EVALUATION OF AUTOMATIC CLASS III DESIGNATION) (2017), 
https://www.fda.gov/media/72674/download (summarizing the De Novo 
Classification pathway). 
 156. Id. 
 157. See Medical Device Exemptions 510(k) and GMP Requirements, U.S. 
FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/315.cfm (last accessed 
Dec. 2, 2019) (listing medical devices exempt from premarket notification and 
premarket approval requirements). 
 158. Id. 
 159. Id. 
 160. See Premarket Notification 510(k), U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/premarket-submissions/premarket-
notification-510k (last updated Mar. 13, 2020). 
 161. Id. 
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premarket approval (PMA) process.162 Devices subject to the 
510(k) premarket requirement are not cleared for market until 
the FDA provides a written order declaring that the device is 
“substantially equivalent” to a predicate device and that it may 
be marketed in the U.S.163 
A device is deemed “substantially equivalent” to a predicate 
device if the following criteria are satisfied: Firstly, it must have 
the same intended use. Secondly, it must either have the same 
technological characteristics, or, if it has different technology 
characteristics that do not raise questions of safety and 
effectiveness, the 510(k) submission must contain information 
demonstrating that the new device is at least as safe and 
effective as the predicate device.164 Technological characteristics 
are deemed to be different if there is a significant change in the 
materials, design, or energy source.165 In considering whether 
there is substantial equivalence to a predicate device, the FDA 
also looks at differences in manufacturing process, labeling, and 
chemical composition.166 The use of nanotechnology in devices is 
likely to make determinations of substantial equivalence and 
technological sameness challenging. 
The FDA has recently provided several alternative 
pathways for manufacturers to show that their devices are 
substantially equivalent.167 The Special 510(k) Program 
provides a simplified pathway for manufacturers to update and 
 
 162. Id. 
 163. Id. 510(k) must also satisfy general controls and any prescribed special 
controls. See Regulatory Controls, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/overview-device-regulation/regulatory-
controls (last updated Mar. 27, 2018). 
 164. See 21 U.S.C. § 360c(i) (2011); see also U.S. FOOD & DRUG ADMIN., supra 
note 146; see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND 
FOOD AND DRUG ADMINISTRATION STAFF: THE 510(K) PROGRAM: EVALUATING 
SUBSTANTIAL EQUIVALENCE IN PREMARKET NOTIFICATIONS (2014), 
https://www.fda.gov/media/82395/download (summarizing the 510(k) decision 
making process, how the FDA interprets substantial equivalence, and how it 
defines technological characteristics). 
 165. 21 U.S.C. § 360c(i)(1)(B) (2011). 
 166. U.S. FOOD & DRUG ADMIN., supra note 146. 
 167. See Tom Cowan, FDA Issues Guidance on “Abbreviated” and “Special” 
510(k) Pathways, KNOBBE MEDICAL, 
http://knobbemedical.com/medicaldeviceblog/article/fda-issues-guidance-on-
abbreviated-and-special-510k-pathways/ (last visited Apr. 17, 2020). 
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modify their own, previously cleared products.168 In a Special 
510(k) submission, a manufacturer can establish substantial 
equivalence by way of its own design controls and conformance 
with quality system regulations.169 The Abbreviated 510(k) 
Program facilitates approval of devices that have been the 
subject of the FDA’s previously-issued product-specific 
guidances, special control standards, or voluntary consensus 
standards.170 In an abbreviated 501(k) application, a 
manufacturer can establish substantial equivalence by following 
such guidances or standards and assuring its conformance.171 
Premarket Approval (PMA) is the most rigorous form of 
premarket review that the FDA conducts for medical devices.172 
The PMA process is roughly analogous to an NDA or Biologics 
License Application (BLA), except that the standard for approval 
of a PMA is a “reasonable assurance” of safety and efficacy.173 A 
PMA application involves submission of data from laboratory 
and clinical studies, device and manufacturing details including 
trade secret information, quality system controls, comparison to 
commercially-available alternatives, and scientifically-based 
 
 168. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF: THE SPECIAL 510(K) PROGRAM (2019), 
https://www.fda.gov/media/116418/download (describing the new Special 510(k) 
program and how to determine whether a product modification is suitable for 
review under this program). 
 169. Id. 
 170. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF: THE ABBREVIATED 510(K) PROGRAM (2019), 
https://www.fda.gov/media/72646/download (summarizing the new Abbreviated 
510(k) program and how to determine whether a product modification is 
suitable for review it). See also U.S. FOOD & DRUG ADMIN., APPROPRIATE USE 
OF VOLUNTARY CONSENSUS STANDARDS IN PREMARKET SUBMISSIONS FOR 
MEDICAL DEVICES (2018), https://www.fda.gov/media/71983/download 
(explaining that voluntary consensus standards are effective regulatory tools 
recognized in the FD&C Act per 21 U.S.C. § 360d(1)(A)). 
 171. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF: THE ABBREVIATED 510(K) PROGRAM (2019), 
https://www.fda.gov/media/72646/download (describing the new Abbreviated 
510(k) program and how to determine whether a product modification is 
suitable for review). 
 172. See Premarket Approval, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/premarket-submissions/premarket-
approval-pma (last updated May 16, 2019); see also 21 C.F.R. § 814 (1996) 
(outlining the PMA process). 
 173. Compare 21 U.S.C. § 393(b) (2011) with 21 U.S.C. § 355(j) (2011). See 
also The Biologics Price Competition and Innovation Act of 2009, S. 1695, 100th 
Cong. § 7002(e) (2007). 
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conclusions linking the device’s medical claims to the results of 
studies.174 The studies should be based on accepted scientific and 
clinical practices and, when applicable, FDA guidances.175 In 
evaluating safety and efficacy, the FDA considers the intended 
patient population, the conditions for use of the device, the risk-
benefit of the device, and the device’s reliability.176 
Follow-on devices gain access to the market the same way 
as new devices. For Class I and II, no premarket review is 
required if the device is an exempted device; otherwise, the 
manufacturer will likely proceed through a 510(k) process. If the 
innovator device requires PMA, then follow-on devices will also 
require a PMA unless the FDA down-classified the device class 
in the interim.177 Moreover, the prior PMA approval would have 
provided the innovator with six years of data exclusivity.178 PMA 
devices do not have an abbreviated approval path that is 
analogous to the generic ANDA pathway.179 The 510(k) path is 
the closest approximation of a follow-on pathway in the device 
framework, which although not used to reference clinical data, 
is similarly used to obtain approval by pointing to an already-
approved product. 
iii. Biologics 
Biologics are regulated under the Public Health and Safety 
Act (PHSA) which requires approval of a BLA prior to marketing 
any biologic.180 Approval is based on the applicant establishing 
that the product is safe, pure, and potent.181 The BLA process is 
 
 174. See PMA Application Contents, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/premarket-approval-pma/pma-
application-contents (last updated May 16, 2019) (outlining required and 
suggested elements of a PMA application). 
 175. See PMA Clinical Studies, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/premarket-approval-pma/pma-clinical-
studies (last updated Feb. 21, 2019) (summarizing best practices for clinical 
investigations and factors that the FDA considers for safety and effectiveness). 
 176. See 21 U.S.C. § 860.7 (2012). 
 177. See Erika Leitzan, Data Exclusivity for Medical Devices, OBJECTIVE 
INTENT (Oct. 10, 2017), https://objectiveintent.blog/2017/10/10/data-exclusivity-
for-medical-devices/. 
 178. Id. 
 179. Id. 
 180. 42 U.S.C. § 262 (1993). 
 181. See Frequently Asked Questions About Therapeutic Biological Products, 
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccines-blood-
biologics/development-approval-process-cber/biologics-license-applications-bla-
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largely analogous to an NDA and, in fact, the PHSA expressly 
adopts for biologics all the general FD&C provisions except for 
the replacement of the NDA process with a BLA.182 A BLA 
differs from an NDA in that BLA holders can have more 
stringent manufacturing validation requirements, must retain 
certain product samples after expiration of each lot of product, 
and have particular post-market responsibilities including 
submission of reports regarding batch information and adverse 
events.183 
Due to the complexity of biologics as well as their economic 
and therapeutic importance, Congress has provided unique 
regulatory provisions for follow-on biologics products.184 The 
Biologics Price Competition and Innovation Act (BPCIA) 
provided for an abbreviated BLA pathway, analogous to an 
ANDA, except that instead of requiring follow-on products to 
have identical structure and activity. The BPCIA permits 
approval of “biosimilar” products that are merely expected to 
produce the same clinical result.185 The FDA defines a product 
as a biosimilar when there are “no clinically meaningful 
 
process-cber (last updated Feb. 2, 2018) (defining biological products and 
summarizing certain ways that approval of biological products differs from the 
drug approval process). 
 182. 42 U.S.C. §262(j) (1993). 
 183. See Keith Webber, FDA’s Interpretation of the “Deemed to Be a License” 
Provision of the Biologics Price Competition and Innovations Act, FDA WATCH, 
https://www.lachmanconsultants.com/wp-content/uploads/2019/03/deemed-to-
be-a-license-20-22-FDA-0319.pdf (summarizing the differences between an 
NDA and BLA). 
 184. See The Biologics Price Competition and Innovation Act of 2009, S. 
1695, 100th Cong. § 7002(e) (2007) (creating an accelerated approval system for 
biological products that are biosimilar to, or interchangeable with, an FDA 
licensed reference biological product). 
 185. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
CONSIDERATIONS IN DEMONSTRATING INTERCHANGEABILITY WITH A 
REFERENCE PRODUCT (2019), https://www.fda.gov/media/124907/download 
(reporting on recent developments in the biosimilar approval process); see also 
U.S. FOOD & DRUG ADMIN., GUIDANCE CLINICAL PHARMACOLOGY DATA TO 
SUPPORT A DEMONSTRATION OF BIOSIMILARITY TO A REFERENCE PRODUCT 
(2016), https://www.fda.gov/media/88622/download; U.S. FOOD & DRUG ADMIN., 
GUIDANCE QUESTIONS AND ANSWERS ON BIOSIMILAR DEVELOPMENT AND THE 
BPCI ACT GUIDANCE FOR INDUSTRY (2018), https://www.fda.gov/regulatory-
information/search-fda-guidance-documents/questions-and-answers-
biosimilar-development-and-bpci-act-guidance-industry; U.S. FOOD & DRUG 
ADMIN., INTERPRETING SAMENESS OF MONOCLONAL ANTIBODY PRODUCTS 
UNDER THE ORPHAN DRUG REGULATIONS (2014), 
https://www.fda.gov/media/77256/download. 
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differences” between the reference product in terms of safety, 
purity, and potency.186 However, a biosimilar is not so similar 
that, for any given patient, one can assume the same clinical 
result when switching from the reference product.187 The 
omission of any requirement for structural sameness or 
bioequivalence is a key distinction between generic drugs and 
biosimilars.188 In some cases, biosimilars can be shown to be 
interchangeable, on the basis of additional clinical testing and 
analysis of switching risks.189 An “interchangeable” biosimilar 
may be substituted for the reference product at the pharmacy-
level without requiring physician intervention.190 Biosimilars 
are a particularly active area of regulatory development as the 
FDA and Congress are still exploring how ‘similar’ biosimilars 
should be.191 
Additionally, unlike the generic approval process for drugs, 
the approval process for biologics does not tether the FDA to the 
patent system. Instead, BLA approval of follow-on products 
follows a process that is separate from an innovator’s patent 
enforcement efforts.192 
F. CONSEQUENCES OF PRODUCT CLASSIFICATION 
Product classification is a critical determining factor of the 
time and cost of obtaining regulatory approval. Development 
and approval of drugs and biologics involves enormous costs, 
estimated to be as high as $100 million to $2 billion.193 Yet, a 
device can be developed and approved with as little as $1 million 
 
 186. Biosimilar and Interchangeable Products, U.S. FOOD & DRUG ADMIN. 
(Oct. 2017), https://www.fda.gov/drugs/biosimilars/biosimilar-and-
interchangeable-products#biosimilar. 
 187. This limits the ability of a pharmacy to substitute certain biosimilars 
for pioneer biologic without the agreement of the prescriber. Id. 
 188. Id. 
 189. Id. 
 190. Id. 
 191. Id. 
 192. Cf. 42 USC § 262(l) (1993) (allowing the so-called “patent dance” process 
in which biosimilar entrants can negotiate an initial, early wave of patent 
litigation during the BLA process, although the FDA’s approval does not hinge 
on any particular litigation outcome). 
 193. Thomas Sullivan, A Tough Road: Cost to Develop One New Drug Is $2.6 
Billion; Approval Rate for Drugs Entering Clinical Development Is Less Than 
12%, POL’Y & MED., https://www.policymed.com/2014/12/a-tough-road-cost-to-
develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-
de.html (last updated Mar. 21, 2019). 
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to $10 million if its developer can follow a 510(k) path.194 Even 
in the case of a device PMA, estimated to have an average cost 
between $10 million and $100 million, costs are still typically far 
below the average cost of development and approval of NDA and 
BLA products.195 Moreover, bringing a new drug or biologic to 
market takes far longer, about twelve years on average, which 
would typically include about two years of pre-clinical testing, 
about eight years of clinical trials, and about two years of 
NDA/BLA approval.196 In contrast, bringing a new device to 
market averages between three and seven years.197 The new 
device timeline would typically include two to three years of pre-
clinical bench and animal testing (which can sometimes be 
sufficient to show that a 510k device is substantially equivalent) 
and can also involve one to two years of clinical trials, which may 
involve a thousand or more patients.198 
This eight-year difference in timeline is enormously 
meaningful. Each additional year of clinical investigation and 
regulatory review not only delays a future income stream, but 
also eats away at the remaining term of the product’s patents.199 
 
 194. See Medical Device User Fees, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/premarket-submissions/medical-device-
user-fees (last updated Jan. 14, 2020) (discussing the different fee and payment 
structures of submitting a drug to the FDA); See also U.S. FOOD & DRUG 
ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION 
STAFF: BUNDLING MULTIPLE DEVICES OR MULTIPLE INDICATIONS IN A SINGLE 
SUBMISSION (2007), https://www.fda.gov/media/73500/download (discussing a 
method of cutting down costs by bundling multiple products into one 
application). 
 195. See U.S. FOOD & DRUG ADMIN. supra note 194 (discussing the different 
fee and payment structures of submitting different types of drugs to the FDA 
for approval). 
 196. Gail A. Van Norman, Drugs, Devices, and the FDA: Part 1: An Overview 
of Approval Processes for Drugs, 1 JACC: BASIC TO TRANSLATIONAL SCI. 70, 70–
79 (2016); see also Matthew Herper, The Cost of Creating a New Drug Now $5 
Billion, Pushing Big Pharma to Change, FORBES (Aug. 11, 2013), 
https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-
cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/#7753cc096bfc. 
 197. Gail A. Van Norman, Drugs, Devices, and the FDA: Part 2: An Overview 
of Approval Processes: FDA Approval of Medical Devices, 1 JACC: BASIC TO 
TRANSLATIONAL SCIENCE 277, 277–87 (2016). 
 198. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF: FORMAT FOR TRADITIONAL AND ABBREVIATED 
510(K)S (2019), https://www.fda.gov/media/130647/download (discussing the 
timeline for submission and approval of 510(k) devices). 
 199. Lifetime Trends in Biopharmaceutical Innovation, QUINTILESIMS (Jan. 
2017), https://www.statnews.com/wp-
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The shorter the remaining patent term, the higher the company 
will need to set its prices in order to counterbalance its 
development and opportunity costs. If the remaining patent 
timeline is too short, then development and commercialization 
of the product may not be justified. 
Each of the different regulatory pathways reward 
applicants with differing periods of data and market 
exclusivity.200 For example, drug products representing a new 
chemical entity (NCE) having a new active moiety201 and 
approved under an NDA pathway will typically be provided with 
five years of data exclusivity per the Hatch-Waxman Act,202 
which also effectively provides more than seven years of market 
exclusivity by way of a thirty-month stay pending generic 
entry.203 Other clinical investigations, for example, studying a 
substantial change to a previously approved drug, can provide 
three years of market exclusivity.204 Devices can be provided 
with six years of data exclusivity after approval of a PMA.205 
Approval of biologic under the BLA pathway provides four years 
of data exclusivity and twelve years of market exclusivity.206 
Various additional incentives further apply to each, such as the 
six-month extension of exclusivity provided for pediatric testing 
and the seven-year market exclusivity provided by the Orphan 
 
content/uploads/2017/01/Lifetime_Trends_in_Biopharmaceutical_Innovation.p
df. 
 200. See Bo Peng & Marta C. Tomas, A Cheat Sheet to Navigate the Complex 
Maze of Exclusivities in the United States, 3 PHARMACEUTICAL PAT. ANALYST 
339 (Oct. 7, 2014), https://www.future-science.com/doi/10.4155/ppa.14.30. 
 201. Here, the term “active moiety” simply refers to a new drug substance, 
not just a new pharmacophore portion of drug. The term “new active moiety” 
serves to distinguish from previously FDA-approved drug substances, and 
esters, salts, and clathrates thereof. See Scott Whittaker & Anthony Walker, 
Pharmaceutical Patent Term Extension: An Overview, ALACRITA, 
https://www.alacrita.com/whitepapers/pharmaceutical-patent-term-extension-
an-overview (last accessed Apr. 16, 2020). 
 202. 34 U.S.C. § 156(g)(6)(C) (2018). 
 203. Id. 
 204. Small Business Assistance: Frequently Asked Questions for New Drug 
Product Exclusivity, U.S. FOOD & DRUG ADMIN. (2016), 
https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-
business-assistance-frequently-asked-questions-new-drug-product-exclusivity. 
 205. See Erika Lietzan, Data Exclusivity for Medical Devices, OBJECTIVE 
INTENT (Oct. 10, 2017) https://objectiveintent.blog/2017/10/10/data-exclusivity-
for-medical-devices/ (summarizing the different data exclusivity provisions 
regarding different medical devices). 
 206. Id. 
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Drug Exclusivity incentive for treatment of a rare disease 
affecting fewer than 200,000 people in the United States.207 
Drug and biologic products can also take advantage of the 
Qualified Infectious Disease Product exclusivity which provides 
five years of supplemental market exclusivity.208 Patent term 
extensions of up to five years are granted to one of a sponsor’s 
U.S. patents covering the product for which premarket testing 
approval was required.209 
As discussed in Section E, classification also controls how 
follow-on competition is regulated. A table is provided below that 
summarizes the differences between the drug, device, and 
biological regulatory schemes. 
 
Table 4. Summary of Differences Between Regulatory 
Pathways 
 Drug Device Biologic 
Premarket 
Review 
NDA PMA, 510(k), or 
none depending on 
risk 
BLA 
Average Time 
for 
Preclinical, 
Clinical, and 
Approval 
12 years 3–7 years 12 years 
Average Cost 
for Approval 
$100M–$2B $1M–$100M $100M-$2B 
Data 
Exclusivity 
5 years  
(Paragraph IV 
can be 
submitted at 4 
years) 
6 years 4 years 
 
 207. FDA Exclusivity and Generic Drugs: What Does It Mean?, U.S. FOOD & 
DRUG ADMIN., https://www.fda.gov/drugs/development-approval-process-
drugs/frequently-asked-questions-patents-and-exclusivity (last updated Feb. 5, 
2020). 
 208. US. FOOD & DRUG ADMIN., DRAFT GUIDANCE, QUALIFIED INFECTIOUS 
DISEASE PRODUCT DESIGNATION QUESTIONS AND ANSWERS GUIDANCE FOR 
INDUSTRY (2018), https://www.fda.gov/media/111091/download. 
 209. U.S. FOOD & DRUG ADMIN., PATENTS AND EXCLUSIVITY (2015), 
https://www.fda.gov/media/92548/download. 
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Market 
Exclusivity 
7.5 years (5 
years plus 30-
month stay) 
 12 years 
Patent Term 
Extension 
≤ 5 years ≤ 5 years ≤ 5 years 
Follow on 
pathway 
505(j) 510(k) Pathway Biosimilar 
Pathway 
Standard of 
Equivalence 
for Follow-On 
Products. 
Same route of 
administratio
n, dosage 
form, and 
strength, and 
bioequivalence
210 
Substantial 
equivalence 
Can be 
expected to 
produce the 
same clinical 
result in any 
given 
patient211 
 
II. ANALYSIS 
A. COMPLEX PRODUCTS HAVE COMPLEX PROBLEMS 
i. The Problem of Rising Healthcare Costs 
Congress is increasingly concerned with the rising costs of 
healthcare and is searching to find new ways to lower 
prescription drug costs.212 Medical innovation is an expensive 
and uncertain process. The cost of this uncertainty is reflected 
in the enormous amount of resources required to develop new 
medical products. After accounting for the cost of clinical 
failures, the total cost of developing a new drug is now estimated 
 
 210. See 21 U.S.C. §355(j)(8)(B) (2010) (defining bioequivalence when the 
rate and extent of absorption of the reference drug do not show a significant 
difference). 
 211. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: 
CONSIDERATIONS IN DEMONSTRATING INTERCHANGEABILITY WITH A 
REFERENCE PRODUCT (2019), https://www.fda.gov/media/124907/download 
(summarizing recent developments in the biosimilar approval process). 
 212. See Shelley Starkey, Congress Seeks to Address Rising Health Care 
Costs, NAT’L COUNCIL FOR BEHAV. HEALTH (May 30, 2019), 
https://www.thenationalcouncil.org/capitol-connector/2019/05/congress-seeks-
to-address-rising-health-care-costs/; see also FDA Drug Competition Action 
Plan, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/guidance-
compliance-regulatory-information/fda-drug-competition-action-plan (last 
updated Apr. 8, 2020). 
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to be as high as $2.6 billion, but of which sixty percent is 
incurred during clinical validation and FDA approval.213 Drug 
candidates can expect a failure rate of more than ninety percent 
and costs of approximately $1.5 billion during clinical testing 
and regulatory approval—that is, most costs are incurred under 
the purview of seeking regulatory approval and within 
frameworks set forth by the FDA.214 The cost and risk of 
development necessarily leads to high drug costs, as innovators 
seek to justify their development expenses while earning a 
return on capital commensurate with their risks of failure. The 
factors that determine pricing of medical products are 
enormously complex, including the cost of existing standard of 
care, perceived value, payor dynamics, patient population, 
length of treatment, geography, and even soft factors like payor 
outcry or political concerns.215 What is clear, at least, is that 
competition can significantly reduce average prices.216 Entry of 
a single competitive generic product can lower prices by thirty to 
forty percent, while the presence of six or more competitive 
products can lower prices by up to ninety-five percent.217 
Complex Products, however, can involve both high development 
costs and unique barriers to competitor entry—this is a recipe 
for runaway drug costs. 
Recent reports from the U.S. GAO identify Complex 
Products as an important area for further regulatory 
development.218 The GDUFA, reauthorized in 2017 (GDUFA II) 
 
 213. Prescription Medicines: Costs in Context, PHARM. RES. & MFRS. AM., 
http://phrma-docs.phrma.org/sites/default/files/pdf/prescription-medicines-
costs-in-context-extended.pdf (last updated Aug. 2016). 
 214. C. Heem et al., Estimation of Clinical Trial Success Rates and Related 
Parameters, 20 BIOSTATISTICS 273, 273–86 (Apr. 2019), 
https://academic.oup.com/biostatistics/article/20/2/273/4817524. 
 215. See, e.g., STAFF OF COMMITTEE OF FINANCE, 114TH CONG., THE PRICE 
OF SOVALDI AND ITS IMPACT ON THE U.S. HEALTHCARE SYSTEM 1, 1–28 (Comm. 
Print 2014), https://www.govinfo.gov/content/pkg/CPRT-
114SPRT97329/html/CPRT-114SPRT97329-Part1.htm (discussing the pricing 
method used to price the drug Sovaldi incorporating these factors). 
 216. WAYNE WINEGARDEN, PACIFIC RESEARCH INSTITUTE, THE ECONOMICS 
OF PHARMACEUTICAL PRICING 5, 5–27 (2014), 
https://www.pacificresearch.org/wp-
content/uploads/2017/06/PhamaPricingF.pdf. 
 217. Generic Competition and Drug Prices, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-
cder/generic-competition-and-drug-prices (last updated Dec. 13, 2019). 
 218. See generally U.S. GOV’T ACCOUNTABILITY OFF., GAO-18-80, GENERIC 
DRUGS: FDA SHOULD MAKE PUBLIC ITS PLANS TO ISSUE AND REVISE GUIDANCE 
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under the FDA Reauthorization Act of 2017 (FDARA), requires 
the FDA to develop a program to facilitate approval of Complex 
Product, especially generics.219 The FDA issued formal letters 
committing to these goals and summarizing specific steps it 
would take.220 These letters, representing a decade of associated 
regulatory objectives, expressly identify Complex Products as an 
area requiring further science-based regulatory development.221 
Prior to departing from the FDA in 2019, former FDA 
Commissioner Scott Gottlieb suggested that legislators further 
consider changing Hatch-Waxman to accommodate complex 
drugs.222 On January 17, 2020, the House Committee on Energy 
 
ON NONBIOLOGICAL COMPLEX DRUGS 12 (2017), 
https://www.gao.gov/assets/690/689047.pdf; see also U.S. GOV’T 
ACCOUNTABILITY OFFICE, GAO-17-452, GENERIC DRUG USER FEES: 
APPLICATION REVIEW TIMES DECLINED, BUT FDA SHOULD DEVELOP A PLAN 
FOR ADMINISTERING ITS UNOBLIGED USER FEES 6–14 (2017), 
https://www.gao.gov/assets/690/684950.pdf (identifying generic competition 
around complex drugs to have unique scientific and regulatory challenges and 
should be a primary focus area for regulatory development). 
 219. See e.g., FDA Reauthorization Act of 2017, Pub L. No. 115-52, 131 Stat. 
1005 (2017) (providing provisions to facilitate generic drug approval, including 
of complex products); see generally GENERIC COMPLEX DRUGS SAFETY AND 
EFFECTIVENESS FOR PATIENTS ACT OF 2015, H.R. 1576, 114TH CONG. (2015) (a 
failed bill proposing to require a study by the Government Accountability Office 
(GAO) to assess the Food and Drug Administration’s current regulatory 
pathway for reviewing generic versions of nonbiologic complex drug products). 
 220. Here, the FDA’s performance goals relate primarily to providing 
product specific guidances. GDUFA II sets an ambitious timeline for the FDA 
to issue product-specific guidance for new generics for ninety percent of drugs 
having NDAs approved after October 1st, 2017, though this timeline does not 
apply to Complex Products, which have scientific and regulatory research 
challenges. See U.S. FOOD & DRUG ADMIN., GENERIC DRUG PERFORMANCE 
GOALS AND PROCEDURES FISCAL YEARS 2018-2022 (2016), 
https://www.fda.gov/media/101052/download (exempting Complex Products 
from its product-specific timeline). 
 221. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE 
GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 (2012), 
https://www.fda.gov/media/82022/download (summarizing various FDA goals 
related to Complex Products, including continued development of science-based 
recommendations for Complex Products, and the FDA’s intention to issue 
guidances to clarify its recommendations); See also U.S. FOOD & DRUG ADMIN., 
GENERIC DRUG PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018-
2022 (2016), https://www.fda.gov/media/101052/download (providing a pre-
ANDA pathway to facilitate development and approval of generic Complex 
Products). 
 222. Beth Wang, Gottlieb: Changes to Hatch-Waxman May Boost Complex 
Generic Market, INSIDEHEALTHPOLICY (Apr. 4, 2019, 12:09PM), 
https://insidehealthpolicy.com/daily-news/gottlieb-changes-hatch-waxman-
may-boost-complex-generic-market (stating that the FDA chief “told lawmakers 
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and Commerce sent a letter to the FDA voicing its concerns 
regarding lagging approvals of Complex Products and 
demanding documents reflecting the FDA’s efforts to date.223  
Currently, Complex Products are regulated according to the 
FDA’s conventional regulatory scheme based on whether the 
product is classified as a drug, device, biologic, or combination 
product. To the extent Complex Products raise new challenges, 
the FDA has preferred to approach each product on a case-by-
case basis as scientifically-grounded guidance cannot be easily 
generalized across Complex Products.224 The FDA’s current 
efforts to facilitate approval of Complex Products are centered 
around increasing transparency, for example, by way of 
guidance225 on frequent trouble areas, reasoning that doing so 
will lead to better prepared applicants and fewer unexpected 
regulatory outcomes.226 The FDA is expected to issue new 
guidance on Complex Products soon.227 To encourage 
competition, the FDA has started publishing a list of all off-
 
they could contemplate changes to Hatch-Waxman that would allow the agency 
to look at small complements of clinical data when approving generics of 
complex drugs”). 
 223. Letter from Frank Pallone, Chairman Comm. Energy and Commerce, 
et al., to Stephen Hahn, Comm’r of U.S. Food & Drug Admin. (Jan. 17, 2020) 
(on file with House Energy Committee). 
 224. Jon S. B. de Vlieger et al., Report of the AAPS Guidance Forum on the 
FDA Draft Guidance for Industry: “Drug Products, Including Biological 
Products, that Contain Nanomaterials”, 21 AM. ASS’N OF PHARM. SCIENTISTS 
55, 55 (Apr. 17, 2019), https://doi.org/10.1208/s12248-019-0329-7 (summarizing 
a meeting discussing appropriate regulatory pathways for drug products 
containing nanomaterials). 
 225. See Guidances, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/industry/fda-basics-industry/guidances (last updated May 
24, 2018) (describing the FDA’s use of guidance documents). 
 226. See U.S. FOOD & DRUG ADMIN., supra note 88 (defining chemical action 
and explaining the FDA’s current thinking on the same). 
 227. See Upcoming Product-Specific Guidances for Complex Generic Drug 
Product Development, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-
guidances-complex-generic-drug-product-development (last updated Mar. 2, 
2020) (listing complex products for which FDA plans to provide additional 
product specific guidances). Such guidances are in line with FDA’s GDUFA II 
commitment letter and Congress’s mandate under FDAMA. See, e.g., U.S. FOOD 
& DRUG ADMIN., GENERIC DRUG PERFORMANCE GOALS AND PROCEDURES 
FISCAL YEARS 2018-2022 (2016), https://www.fda.gov/media/101052/download; 
see also FDA REAUTHORIZATION ACT OF 2017, PUB. L. NO. 115-52, §§501-905, 
131 STAT. 1005, 1036– 90 (2017) (providing provisions to facilitate generic drug 
approval, including generic complex products). 
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patent approved drugs that have no generic competition.228 The 
FDA has also committed to issuing more product-specific 
guidance, targeting ninety percent of all new chemical entity 
drugs, but does not expect to meet that mark for Complex 
Products.229 Product specific guidance for Complex Products 
requires the development of scientific recommendations.230 The 
FDA has also set up a Pre-ANDA Program and a mid-review 
meeting program to assist applicants developing Complex 
Products.231 The goal of the program is to speed up the approval 
process for generic Complex Products, but also to inform 
innovators regarding the FDA’s intended approach for 
bioequivalence alternatives and other product-specific 
challenges. 
Each of these programs aim to decrease regulatory 
uncertainty and facilitate competition primarily by increasing 
FDA communication. However, the challenges surrounding 
Complex Products are statutory and technical in nature, not a 
result of lacking FDA transparency. The statutory problem is 
that the FD&C Act relies on inherently flawed chemistry-based 
distinctions to delineate its regulatory framework. The 
 
 228. List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic, 
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/abbreviated-new-drug-
application-anda/list-patent-exclusivity-drugs-without-approved-generic (last 
updated Dec. 13, 2019). See also Approved Drug Products with Therapeutic 
Equivalence Evaluations (Orange Book), U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. (last updated Apr. 
2020) (listing all approved drug products, including corresponding patents that 
must be overcome prior to marketing a generic). 
 229. See U.S. FOOD & DRUG ADMIN., HUMAN GENERIC DRUG PERFORMANCE 
GOALS AND PROCEDURES FISCAL YEARS 2013-2017 (2012), 
https://www.fda.gov/media/82022/download (summarizing various FDA goals 
related to Complex Products, including continued development of science-based 
recommendations for Complex Products, and FDA’s intention to issue guidances 
to clarify its recommendations); see also U.S. FOOD & DRUG ADMIN., GENERIC 
DRUG PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018-2022 (2016), 
https://www.fda.gov/media/101052/download (providing a pre-ANDA pathway 
to facilitate development and approval of generic Complex Products). 
 230. Id. 
 231. See U.S. FOOD & DRUG ADMIN., FORMAL MEETINGS BETWEEN FDA AND 
ANDA APPLICANTS OF COMPLEX PRODUCTS UNDER GDUFA: GUIDANCE FOR 
INDUSTRY (2017), https://www.fda.gov/media/107626/download (explaining that 
mid-review-cycle meetings are used “to discuss issues identified during review 
with the applicant”); see also U.S. FOOD & DRUG ADMIN., GDUFA II 
COMMITMENT LETTER (2016), https://www.fda.gov/media/101052/download 
(providing a pre-ANDA pathway to facilitate development and approval of 
generic Complex Products). 
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technological problem is that development of follow-on 
competition for Complex Products requires substantial, but 
redundant, technological efforts on the part of each applicant. 
ii. The Problem with Chemical Action 
Congress requires the FDA to distinguish devices from 
drugs and biologics based on whether the intended therapeutic 
function involves chemical action on the human or animal body, 
or if the function is dependent on metabolism. However, the 
precise meaning of chemical action is a frequent area of 
confusion that leads to significant uncertainty, particularly in 
the case of drug-device combinations and products having both 
device-like and drug-like characteristics.232 The FDA’s reliance 
on this distinction has led to unintuitive product 
classifications.233 For drug-device combination products, 
nanodevices, or other devices involving nanotechnology, the 
uncertainty of classification poses a significant regulatory risk. 
Experts have wrestled with how to rationalize the chemical 
action requirement in a manner that provides a predictable 
result. One analysis suggests interpreting chemical action 
occurs when there is (1) a chemical transformation occurring at 
the site of treatment and involving the article, (2) the 
transformation is causally linked to the therapeutic effect, and 
(3) the transformation is consistent with concepts currently 
considered as chemistry.234 While this is a useful framework, 
 
 232. See FDA Finalizes Product Classification Guidance, FDA L. BLOG (Oct. 
3, 2017), http://www.fdalawblog.net/2017/10/fda-finalizes-product-
classification-guidance/ (explaining how earlier draft guidance topics on the 
subject of chemical action were criticized by numerous objections); see also Drug 
or Device?—FDA Provides More Clarity—Or Does It?, CAMARGO BLOG (Oct. 11, 
2017), https://camargopharma.com/resources/blog/drug-device-fda-clarity 
(explaining that the FDA issued a guidance document in response to the 
difficulty in understanding whether “a combination product would be reviewed 
as a device or a drug”); see generally Koolage & Hall, supra note 97 (discussing 
what is meant by “chemical action” and its significance). 
 233. See Letter from Dep’t of Health and Human Services to Dr. Ronald A. 
Sherman (Oct. 7, 2002) (online at https://www.fda.gov/media/74541/download) 
(explaining that “medical maggots do not meet the definition of a medical device 
in that that they appear to achieve their primary intended purpose through 
chemical action” and are instead “a biological product, as defined by the Public 
Health Service Act”). 
 234. See Koolage & Hall, supra note 97, at 1414. 
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there remains a question about what types of transformations 
should be deemed to be consistent with chemistry.235 
Recent FDA guidance regarding chemical action attempts to 
further define chemical action by introducing the concept of 
interaction “at the molecular level” and mediating “a bodily 
response” or altering a foreign entity’s interaction with the 
body.236 The guidance also clarifies that chemical action excludes 
interactions mediated solely by thermal and electromagnetic 
radiation.237 This updated definition provides surprisingly little 
clarity when considering Complex Products and other device-
like products having functional nanotechnology-based 
features.238 Indeed, the definition permits such a broad 
definition of chemical action that it encompasses virtually any 
interaction beyond purely electromagnetic and kinetic energy 
transfers. 
As the “central” science, chemistry describes the 
mechanisms by which virtually all substances interact. When 
examined on the molecular or “nano” scale, virtually all medical 
products interact with their surroundings by way of chemical 
interactions. For example, even a scalpel can be described as 
involving chemical action: the tool disrupts Van der Waals239 
 
 235. It may be easier to carve things away from chemistry if looking 
“downward” toward the field of physics rather than “upward” toward molecular 
ensembles and macroscopic phenomena. For example, one could carve out 
physical phenomena such as universal force interactions, subatomic changes, 
quantum-based changes, and changes in internal molecular states like 
vibrational, translational, and thermal energy states. This appears to be what 
the FDA has determined in its recent guidance and is similar to the 
“chemicality” principal suggested by Koolage and Hall. See id. at 1410–11. 
However, both of these approaches do not address how to delineate between 
nonspecific chemical interactions, chemically-specific resulting from 
macroscopic devices, device-like interactions on the nanoscale, and other 
nanotechnology-type interactions that rely on aspects like structural design, 
particle size, pore size, and machine-like mechanics. 
 236. See U.S. FOOD & DRUG ADMIN., supra note 88 at 7 (“[A] product exhibits 
‘chemical action’ if it interacts at the molecular level with bodily components 
(e.g., cells or tissues) to mediate (including promoting or inhibiting) a bodily 
response, or with foreign entities (e.g., organisms or chemicals) so as to alter 
that entity’s interaction with the body.”). 
 237. Id. at n.12. 
 238. See generally Raj Bawa et al., Nanopharmaceuticals: Patenting Issues 
and FDA Regulatory Challenges, 5 A.B.A. SCITECH LAW, no. 2, 2008, at 2–3 
(describing the FDA’s regulatory framework for nanopharmaceuticals).. 
 239. Van der Waals forces are electrical interactions that provide the 
adhesive force that holds complex mixtures (like the human body) together. All 
molecules have a given distribution of positive and negative charge across the 
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interactions and non-covalent bonding240 while stretching and 
separating tangled biopolymers to divide tissue.241 Consider a 
very tiny scalpel: Is there a point at which the scalpel is so small 
that it becomes a drug? Should it matter whether someone is 
controlling the scalpel or whether the scalpel is adapted for a 
specific type of tissue or biopolymer? Existing explanations of 
chemical action have trouble distinguishing between drugs and 
devices when both products can be said to interact with the body 
via the same type of chemical interactions.242 
These are the types of interactions one would expect in 
Complex Products like low-weight heparins and carbohydrate 
complexes. For example, pentosan polysulfate sodium is a low-
weight “heparin-like macromolecular carbohydrate derivative” 
indicated for relief of interstitial cystitis.243 It is classified by the 
FDA as a drug.244 While its structure and mechanism are not 
fully known, the drug is thought to collect on the bladder wall 
and adhere to mucosa, thus serving as a protective coating.245 
Here, the therapeutic effect of the drug is unlikely to involve any 
chemical changes of the article itself. Instead, the drug likely 
interacts with the body by way of non-specific electrostatic and 
non-covalent intermolecular interactions. These are the same 
chemical interactions that govern most macroscopic 
interactions, such as the adhesiveness of a bandage, the 
lubricating and cushioning effect of an ointment, the ability of 
soap to dislodge filth, and the cohesive integrity of artificial 
 
electron cloud that constitutes the molecule’s structure, but the presence of 
other molecules nearby shifts this charge distribution. Naturally, some parts of 
one molecule will tend toward positive, while parts of another will tend toward 
negative. Van der Waals forces can be thought of as the result of these attractive 
interactions. 
 240. Non-covalent bonding includes hydrogen bonding, which mediates 
many solvent-based effects and protein folding. 
 241. See generally J.G. Williams et al., Fundamentals of Cutting, 6 
INTERFACE FOCUS 1 (2016) (discussing the mechanics of cutting), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843621/pdf/rsfs20150108.pdf. 
 242. For example, interacting with the body via non-bonding Van der Waals 
interactions and generalized non-covalent intermolecular binding. 
 243. Elmiron, U.S. FOOD AND DRUG AMIN., 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020193s009lbl.pdf 
(last accessed Apr. 17, 2020). 
 244. See U.S. FOOD & DRUG ADMIN., LIST OF OFF-PATENT, OFF-EXCLUSIVITY 
DRUGS WITHOUT AN APPROVED GENERIC (2019), 
https://www.fda.gov/media/133524/download (listing pentosan polysulfate 
sodium as a drug). 
 245. See Elmiron, supra note 238. 
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skin.246 The fields of statistical mechanics and material science 
provide models relating how macroscopic activity relates to 
chemical activity.247 A detailed enough inquiry of any given 
therapeutic effect should virtually always uncover some type of 
chemical action.248 
Lastly, even if a consistent rationale can be provided to 
delineate between drugs and devices based on chemical action, 
there is a problem that such a rationale may not ultimately line 
up with Congress’s primary purpose for such a distinction. Any 
valid interpretation of Congress’s purpose should reflect a non-
arbitrary policy goal. 
iii. The Problem with the Sameness Requirement for Drugs. 
Classification as a drug, rather than as a device or biologic, 
results in enormous consequences for later follow-on 
development of competitor products. For drugs, the path for 
follow-on approval, an ANDA, is achieved by developing a 
generic having the same active ingredient, route of 
administration, dosage form, and strength as a previously 
approved reference product, and showing bioequivalence of the 
same. That is, the pathway for follow-on drugs requires 
sameness, and thus is far narrower than the pathway for 
biosimilars and 510(k) devices.249 This sameness requirement 
arose during an era when most drugs were based on small 
molecules that could be evaluated based on bioavailability and 
 
 246. See Benjamin E. Russ, What Exactly Is the Physical or Chemical Process 
that Makes Adhesive Tape Sticky?, SCI. AM. (July 14, 1997), 
https://www.scientificamerican.com/article/what-exactly-is-the-physi/ 
(explaining “[w]hen two materials are brought into contact with each other, the 
surface molecules interact, giving rise to attractive forces that may be physical, 
chemical, or electrostatic”). 
 247. See HARVEY GOULD & JAN TOBOCHNIK, STATISTICAL AND THERMAL 
PHYSICS WITH COMPUTER APPLICATIONS 2 (2010) (characterizing statistical 
mechanics as “a bridge between the microscopic and macroscopic worlds”). 
 248. On the other hand, one rigorous philosophical inquiry has suggested 
that the presence of chemical action is not enough if it is sufficiently linked 
causally, too remote from the site of treatment, or not grounded in the article 
itself. See Koolage & Hall, supra note 97 (exploring challenges related to 
defining chemical action, including the questions of where in the causal chain 
the chemical action occurs, and how removed the chemical can be from the site 
of therapeutic action). 
 249. See U.S. FOOD & DRUG ADMIN, ABBREVIATED APPROVAL PATHWAYS FOR 
DRUG PRODUCT: 505(B)(2) OR ANDA? (2019), 
https://www.fda.gov/media/130898/download (explaining how “active 
ingredient sameness” is evaluated). 
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which had a readily characterizable and reproducible active 
ingredient. Today, many drugs involve complex structures, for 
which demonstrating sameness may not be feasible.250 
Bioequivalence is also problematic for complex products, which 
may involve unconventional methods of conveying the drug to 
the site of action, for instance, drugs involving nanotechnology-
based carriers or device-controlled delivery.251 Lack of an 
alternative drug pathway based on “similarity” rather than 
“sameness” gives competitors fewer options for developing a 
competing complex drug product. 
Complex drug products thus present three barriers likely to 
increase prices and reduce competition: (1) high costs to develop 
and approve pioneer product; (2) technological challenges to 
producing follow-on competition; and (3) regulatory restrictions 
to follow-on competition. Table 5 illustrates the consequences 
that converge when Complex Products are classified as drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 250. For example, NBCDs might not contain a single, discrete active 
ingredient, or it may not be feasible to show bioequivalence. See Food Drug 
Cosmetic Law Reports Letter No. 2570, Food Drug Cosm. L. Rep. 839392 
(C.C.H.), 2018 WL 839392, at 8–9. 
 251. See JAMES T. O’REILLY & KATHARINE A. VAN TASSEL, FOOD AND DRUG 
ADMINISTRATION §13:131 (4th ed. 2019) (describing the “challenges of reviewing 
generic versions of nonbiological complex drugs”); see also In re Restasis 
(Cyclosporine Ophthalmic Emulsion) Antitrust Litig., 352 F. Supp. 3d 207 
(E.D.N.Y. 2019) (deciding a motion to compel discovery on documents related to 
a suit brought by buyers of a dry-eye medication); Exhibit 13, In re Restasis, 
352 F. Supp. 3d 207 (E.D.N.Y. 2019) (No. 1:18-md-02819-NG-LB) (describing 
how non-biological complex drugs, such as RESTASIS, require thorough 
analysis to evaluate bioequivalence). 
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Table 5. Consequences of Classification on Example 
Medical Products 
Medical 
Product 
Classifica
tion 
Cost to 
Get 
Approval 
Does 
Current 
Technology 
Permit 
Follow-On 
Competition 
Based on 
Readily-
Validated, 
Measurable 
Physical 
Properties? 
Does the 
Current 
Legal 
Regime 
Permit 
Follow-On 
Competitio
n Based on 
Similar 
Properties? 
An artificial 
hip implant.  Device Low Yes 
Yes 
Small 
Molecule Drug Drug High Yes No 
A recombinant 
human 
granulocyte 
colony 
stimulating 
factor. 
Biologic High No Yes 
A complex 
mixture of 
non-biological 
materials that 
self-assemble 
into a variety 
of structural 
forms having 
features on the 
nanoscale. . . 
Example of a complex product. 
 
The burden of approval and barriers to 
competition depend on classification. 
. . . 
primarily for 
serving a 
mechanical 
purpose in the 
human body. 
Device Low No Yes 
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 . . . primarily 
for measuring 
or identifying 
a condition of 
the human 
body. 
Drug High 
No. 
 
Complex products 
classified as drugs suffer 
from both technological 
and legal barriers to 
follow on competition. 
 . . . primarily 
for acting as a 
depot for 
extended 
release of 
drugs. 
Drug High 
 . . . primarily 
for inducing 
immune 
activity. 
Drug High 
 
iv. Technological Challenges of Complex Products. 
Technological challenges, not regulatory issues, likely 
represent the greatest barrier to Complex Product competition. 
For Complex Products, it can be incredibly challenging to 
scientifically prove “sameness” or other types of equivalence, 
when structure and function are not yet fully understood. 
Typically, those who try to bring follow-on Complex Products to 
market must do substantial additional research and 
development, particularly with respect to structure-function 
validation, and sometimes involving additional clinical trials.252 
Even though an innovator may have obtained approval for a 
complex new product, it is another thing entirely for a 
competitor to learn how the product’s structure, manufacture, 
and function interrelate, and then produce it and obtain FDA 
approval. Follow-on competitors must conduct further research 
prior to seeking approval to address these concerns.253 This 
 
 252. See C. Lee Ventola, Biosimilars: Part: Proposed Regulatory Criteria for 
FDA Approval, 38 PHARMACY & THERAPEUTICS 270, 270 (2013) (explaining that 
“[t]he structure–function relationships of biologics are very sensitive”). 
 253. For example, Complex Products may involve nuances to structural 
aspects or sensitive manufacturing relationships that influence therapeutic 
properties. An attempted copy of a Complex Product may appear to have all the 
same recognizable and obvious features, but overlooked or indecipherable 
nuances may be essential to achieving the desired therapeutic effect. See Luke, 
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research burden represents a significant “technological” barrier 
to follow-on competition. 
Secondly, there is a problem that such research efforts are 
redundant. Prior to obtaining approval of a Complex Product, 
the innovator likely dedicated significant resources into 
researching the structural, functional, and manufacturing 
tolerances of its product. This research may relate to deciphering 
which minute manufacturing aspects are acceptable and which 
are not, or it may relate to a way of characterizing structure that 
can be used to discern equivalent versus non-equivalent versions 
of the product. The results of this research are economically 
valuable but often not suitable for patent protection.254 
Accordingly, such information is typically kept as a trade 
secret.255 Clinical data generated by the innovator and shared 
with the FDA will ultimately be made available after approval 
of its product, but usable only after any period of data exclusivity 
 
supra note 1 (describing the regulatory process for pre-ANDA Complex Generic 
Products); see also Jiang, supra note 1 (describing the considerations involved 
in analyzing complex generic drugs); see also U.S. FOOD & DRUG ADMIN. OFFICE 
OF GENERIC DRUGS, 2019 ANNUAL REPORT: ENSURING ACCESS TO SAFE, 
AFFORDABLE, AND EFFECTIVE GENERIC DRUGS (2019), 
https://www.fda.gov/media/135329/download (providing an overview of the 
generic drug state of affairs); see also FED. DRUG ADMIN., GENERIC DRUG USER 
FEE AMENDMENTS (GDUFA) SCIENCE AND RESEARCH PRIORITY INITIATIVES 
FOR FISCAL YEAR 2020 (2020), https://www.fda.gov/media/132370/download 
(listing FDA’s priority initiative regarding the acceleration of access to generic 
drug products); see also Vinod Shah, Non-Biological Complex Drugs: Challenges 
for Approval Standards and Opportunities!, NON-BIOLOGICAL COMPLEX DRUGS 
(NBCD) WORKING GROUP (Apr. 22, 2019), 
https://www.fda.gov/media/125176/download (discussing challenges for 
approval standards of NBCDs). 
 254. See infra Section II(B)(ii). For example, it may be vulnerable to attack 
on obviousness or anticipation grounds over the innovator’s own pre-clinical 
disclosures. Such information is often developed late in the development process 
while conducting detailed investigations of scale-up manufacturing and 
validation. Sometimes even if a patent were obtained based on the new 
information, it may be vulnerable to work around or difficult to enforce. In other 
cases, the information relates to similar products, but not the approved product, 
so any resulting patent would not sufficiently protect the innovator’s own 
product. 
 255. See Kristan Lansbery, Protecting Trade Secrets in the Medical 
Approval Process, https://www.fdli.org/2018/04/update-protecting-trade-
secrets-medical-product-approval-process/ (last accessed August 15, 2020) 
(discussing the value of maintaining trade secrets of medical products during 
FDA approval).  
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expires.256 In contrast, the information kept as a trade secret 
might never be shared. 
When competitors subsequently pursue follow-on products, 
they must independently and redundantly develop an 
understanding of the structural, functional, and manufacturing 
tolerances of the product in order to reproduce a product with 
the requisite sameness or therapeutic equivalence. These 
development efforts must be underway well before any earlier 
research will be publicly disclosed, in order to obtain generic 
approval at the earliest opportunity. Moreover, each competitor 
will likely keep their own results secret from each other, thus 
resulting in further redundant efforts. 
B. PROPOSED SOLUTION—RETHINKING CHEMICAL-BASED 
STATUTORY LANGUAGE AND TECHNOLOGICAL BARRIERS TO 
COMPETITION 
Rethinking the chemistry-based requirements of 21 U.S. 
Code § 321(h)(3) and 21 U.S.C. §355(j) will better align 
regulatory burdens and incentives, reduce regulatory 
uncertainty, and provide more appropriate pathways for 
Complex Product competition. One possible resolution is 
incentivizing disclosure of pro-competitive information in 
exchange for a period of exclusivity. 
First, a clearer definition of Complex Products is needed. 
This Note suggests the following definition, which is couched in 
terms of the technological uncertainty related to establishing 
equivalence: 
A Complex Product is a drug, device, biologic, or 
combination product for which the critical qualities necessary for 
determining equivalency of relevant follow-on products are not 
predictably ascertainable using publicly known technology. 
For example, Complex Products can include products that 
exhibit: structural complexity in which the structural aspects 
that influence safety or efficacy cannot be predictably 
ascertained, characterized, or controlled using publicly known 
technology; functional complexity in which the functional 
properties, including physiologic properties, that influence 
safety or efficacy cannot be predictably ascertained, modeled, or 
controlled using publicly known technology; and operational 
 
 256. Such data exclusivity periods are statutorily prescribed and provide an 
essential window for innovator profitability that delays generic entry. 
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complexity in which the use or operation of the product 
influences safety or efficacy in a manner which cannot be 
predictably ascertained, modeled, or controlled using publicly 
known technology. 
i. Redefining Chemical Action As Biochemical Action 
The chemical action clause should be interpreted to provide 
a non-arbitrary result, even in borderline cases. A proper 
definition of “chemical action” should result in a delineation 
between drugs and devices that reflects a meaningful legislative 
goal, not simply an attempt to square Congress’s word choice 
with current scientific understanding. In 1970, President 
Richard Nixon established the Cooper Committee to report on 
the need for medical device legislation, noting that devices 
present different issues than drugs.257 When Congress passed 
the Medical Device Amendments of 1976, it specifically 
introduced a new risk-based approach to the FDA’s premarket 
review.258 Devices were considered to pose different risks based 
on recognizing how much control an operator had over the 
therapeutic effect and any risk of harm.259 Indeed, the device 
regulatory scheme is organized around general and special 
controls providing a reasonable assurance of safety and efficacy. 
In contrast, new drugs were considered to always require 
rigorous premarket approval and clinical evaluation. When 
Congress passed the Medical Device Amendments of 1976, it 
introduced its risk-based approach to devices only, establishing 
that devices would be treated differently than drugs and that 
chemical action would distinguish devices from drugs.260 The 
 
 257. See A History of Medical Device Regulation & Oversight in the United 
States, U.S. FOOD & DRUG ADMIN. (June 24, 2019), 
https://www.fda.gov/medical-devices/overview-device-regulation/history-
medical-device-regulation-oversight-united-states (noting that the committee 
“[r]ecommended that any new legislation be specifically targeted to the devices 
because devices present different issues than drugs”). 
 258. See id. (noting that the act “[c]reated a three-class, risk-based 
classification system for all medical devices”). 
 259. See Regulatory Controls, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/medical-devices/overview-device-regulation/regulatory-
controls (last updated Mar. 27, 2018) (“Each device is assigned to one of three 
regulatory classes: Class I, Class II or Class III, based on the level of control 
necessary to provide reasonable assurance of its safety and effectiveness.”). 
 260. See id. (describing intent of amendments as to “provide reasonable 
assurance of the safety and effectiveness”); See also 21 U.S.C. §201(h) (defining 
a “device”). 
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FDA has since interpreted “chemical action” based on a purely 
scientific, but overly literal, definition.261 This leads to results 
that can be arbitrary, based on scientifically dated semantics, 
rather than based on risk to patients. 
A different statutory interpretation of chemical action 
would permit the FDA more flexibility to avoid arbitrary 
classification of drugs and devices. First, “chemical action within 
or on the body of man or . . . dependent upon being 
metabolized . . . ”262 should be interpreted as referring to the 
chemical processes that provide for the complex functioning of 
the body, i.e., biochemistry. Second, the statutory requirement 
that a device does not “achieve its intended purposes through 
chemical action,”263 reflects that chemical action is an intrinsic 
quality of the article itself, and that there is a distinction 
between therapeutic results that arise as a result of this intrinsic 
quality, rather than by other means. Moreover, it should be clear 
that Congress intended the chemical action distinction to be 
consequence driven.  
The following two-step inquiry, based on the above-
suggested interpretation of chemical action, should be used to 
determine if a product can be a device: 
1) Is the primary intended purpose achieved due to (a) 
extrinsic control over the article by a human or (b) intrinsic 
features of the article? If (a), the product can be a device. If (b), 
continue to step 2. 
2) If step 1 is (b), are the intrinsic features of the article 
expected to modulate or participate in any specific biochemical 
or metabolic functioning of the human or animal? If not, then the 
product can be a device. 
One benefit of this interpretation is that it ties classification 
to expected risk of biological consequences that cannot be 
predictably controlled. This two-step inquiry narrows the 
concept of “chemical action” to focus specifically on the type of 
chemical action occurring in humans and animals, and thus 
avoids an interpretation that could apply to virtually all medical 
products. The intrinsic versus extrinsic distinction serves to 
identify the therapeutic function that derives from the product 
 
 261. See U.S. FOOD & DRUG ADMIN., supra note 88 at 7 (2017) (expounding 
on the definition of “chemical action”). 
 262. 21 U.S.C. §201(h) (2011) (defining a “device”). 
 263. Id. 
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itself, e.g., a chemical structure, rather than deriving the 
therapeutic function from the skill of a user.264 Another benefit 
is that this interpretation satisfactorily provides a means to 
classify Complex Products and other borderline cases in a 
manner that is non-arbitrary and based on expected 
consequences in patients. 
ii. Applying a Standard Beyond Sameness 
The sameness requirement for drug follow-on products is 
overly limiting: some products that are classified as drugs have 
greater tolerance to structural variation than did traditional 
small-molecule drugs.265 There should be alternative approval 
paths for follow-on drugs when the FDA expects that such 
products would likely be safe and effective despite being merely 
“similar” or “substantially equivalent” to the reference product. 
The follow-on drug pathway should be updated to 
incorporate the “similar” pathway from biologics and the 510(k) 
pathway from devices. This change could be implemented by 
qualifying each new approved product according to its tolerance 
to structural variation and risk. For example, an approved drug 
that has different therapeutic properties when the structure is 
altered should be limited to a sameness-type (ANDA) path. For 
approved drugs that demonstrate that minor variations can 
result in the same therapeutic effects, a similar-type 
(biosimilars) path would be suitable. For approved drugs where 
significant variations could be possible without effecting 
therapeutic effects, for instance, surfactant-based products or 
 
 264. An alternative analysis focused on locality, singularity, and causality, 
which are loosely analogous to the therapeutic effect deriving from intrinsic 
properties of the article. See Koolage & Hall, supra note 94. 
 265. When the Hatch-Waxman Act was enacted, drugs were primarily based 
on small molecule compounds. Such compounds typically had very narrow 
tolerance for structural variation—even replacing a single atom or functional 
group risked unexpected properties. Gerald J. Mossinghoff, Overview of the 
Hatch-Waxman Act and Its Impact on the Drug Development Process, 54 FOOD 
& DRUG L.J. 187, at 190 (1999) (“One major assumption underlying the Hatch-
Waxman Act was that duplicates of pioneer drugs would be the same as the 
innovator’s drug.”) See also Is Biosimilar Insulin Available?, BIOSIMILARS 
RESOURCE CTR., https://www.biosimilarsresourcecenter.org/faq/biosimilar-
insulin-available/ (explaining that, for historical reasons, insulin is regulated 
as a drug and so biosimilar competition is not legally permitted, while at the 
same time generic competition is not technologically feasible since insulin is not 
a small molecule drug for which exact structural duplicates can be made by a 
follow-on competitor). 
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pH neutralization products, then a 510(k)-type pathway would 
be suitable for follow-on competition. 
 
Table 6. Summary of Different Rationales for Permitting 
Follow-On Product Entry. 
Sameness-type Similar-type 510(k)-type 
Minor variations in 
chemical structure 
of an active 
ingredient are not 
permitted because 
minor variations 
would be expected to 
provide different 
therapeutic effects. 
Minor variations in 
chemical structure 
may be permitted 
where the product is 
expected to produce 
the same clinical 
result. 
Significant 
variations in 
chemical structures 
may be permitted 
where such 
variations would not 
be expected to 
reduce the safety or 
functioning of the 
device. 
 
The benefits of this approach are that it would permit 
additional paths for follow-on competition of drugs and conform 
the regulatory framework for follow-on products across classes. 
This also permits the FDA additional flexibility to determine the 
appropriate, science-based restrictions on follow-on products. 
iii. Incentivize Early Disclosure of Pro-Competitive 
Information 
Significant research is required to determine how to 
separately produce Complex Products that are therapeutically 
equivalent to a reference product. When a competitor pursues 
approval of a generic or similar, there is a question regarding 
precisely how identical or similar the Complex Product must be 
in order to be therapeutically equivalent.266 Each competitor 
must independently and redundantly solve this problem to the 
FDA’s satisfaction before it will receive approval.267 However, 
similar problem-solving efforts occur during an innovator’s 
pioneer development efforts. For example, the innovator may 
 
 266. See Jiang, supra note 1, at 25 (posing the question “[h]ow similar is 
equivalent?”). 
 267. See Shah, supra note 1, at 4 (explaining that non-biological complex 
drugs “cannot be fully characterized by physicochemical analytical means” and 
stating that “[a] well-controlled robust manufacturing process is fundamental 
to ensure quality, safety and efficacy”). 
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discover during product optimization that certain variations in 
structure (such as variation in particle sizes, crystal shapes, 
glycosylation patterns, or polymer-chain distribution) might 
cause the product to fail while other changes result in an 
equivalently functioning product. During manufacturing scale-
up, the innovator may discover nuanced manufacturing details 
(such as the importance of a steel tanks, a delay between process 
steps, or the order excipients are added), which might influence 
therapeutic functioning but for which no structural difference 
can be determined. During clinical trials, the innovator might 
discover that the way the product is used is influenced by 
seemingly trivial features (such as the color or shape of an 
inhaler influencing how deeply a patient breaths). These types 
of findings can identify critical quality attributes that are 
relevant to obtaining a conforming pioneer product, or they can 
be relevant to understanding which minor variations will be 
therapeutically equivalent. Fortunately, such discoveries 
naturally arise as a normal part of preparing a pioneer new drug 
for FDA approval, e.g., when studying characterization, batch 
conformation, method validation, and product specifications. 
Yet, the innovator has every reason to keep such insights as 
confidential trade secrets and no incentive to disclose them to 
the public—especially if a patent is unavailable because the 
innovator’s prior disclosed product inherently embodied the 
same parameters. As a result, competitors must redundantly 
labor to uncover know-how that was likely previously 
ascertained by the innovator.268 This represents a redundant, 
cumulative waste of resources that contributes to the high cost 
of health care.269 
Redundant and costly development efforts can be eliminated 
by incentivizing early disclosure of critical quality attributes for 
 
 268. See U.S. FOOD & DRUG ADMIN., supra note 60 at 5 (“Liposome drug 
products are sensitive to changes in the manufacturing conditions . . . . 
Appropriate process controls should be established during product 
development. Prior knowledge can be leveraged and risk assessment techniques 
can be used to identify manufacturing process parameters that potentially 
affect finished product quality.”). 
 269. See Scott Gottlieb, M.D., Reducing the Hurdles for Complex Generic 
Drug Development, U.S. FOOD & DRUG ADMIN. (Oct. 2, 2017), 
https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-
experts/reducing-hurdles-complex-generic-drug-development (“While the FDA 
doesn’t control drug pricing, our policies do affect competition in the market. 
This is the nexus of our current efforts on drug pricing.”). 
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therapeutic equivalence. The patent system is the primary 
governmental tool for incentivizing disclosure of new and useful 
technological progress.270 Yet, present patent doctrine will not 
reward a party that discloses additional information about key 
qualities of a previously used or disclosed product, even if those 
qualities were never appreciated or are critically important for 
the development of a competitive equivalent product. Several 
aspects of patent doctrine prevent innovators from patenting 
subsequent discoveries about features of earlier inventions, and 
yet the doctrine also lends little support to competitors seeking 
to make therapeutic equivalents of an innovator’s product. These 
aspects of the doctrine include: (1) a prior disclosure of a species 
anticipates a subsequent broader, encompassing genus; (2) an 
invention is anticipated if a prior disclosure invention inherently 
had the same features, even if not appreciated; (3) there is no 
requirement that a patent disclosure should enable quick, low-
cost copying; and (4) there is no requirement that a patent 
disclosure identifies features critical for meeting FDA’s 
bioequivalence requirements. 
 
 
 
 
 
 
 
 
Scheme 1 
 
A patent, with its many embodiments, can be represented 
as illustrated in Scheme 1. The outer perimeter represents the 
scope of the broadest disclosure. The block dot represents a lead 
product, submitted to the FDA pending approval. Other 
 
 270. Rebecca S. Eisenberg, The Shifting Functional Balance of Patents and 
Drug Regulation, 19 HEALTH AFF. 119, 123 (2001) (“It is awkward to meet such 
[pharmaceutical] industry-specific needs for exclusivity through provisions of a 
unitary patent system designed to provide innovation incentives for all 
industries.”). 
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products also fall within the scope of the patent’s claims. These 
other products, represented by white dots, might have 
equivalent, or different, functioning compared to the clinical 
candidate. The written description and enablement 
requirements under 35 U.S.C. §112 require that patents clearly 
define the claim scope and describe how to “enable” others to 
make and use the claimed invention, even if doing so would be 
time-consuming, expensive, and involve reasonable 
experimentation.271 There is no requirement that enablement 
describe how to make an exact copy of the product that FDA 
ultimately approves, or even how to make a therapeutically 
equivalent product. Moreover, nothing in the patent doctrine 
requires an innovator to identify which of its embodiments are 
equivalent to the others, or how exactly a competitor should 
optimize manufacturing to achieve matching therapeutic 
equivalence.  
Scheme 2 
 
Scheme 2 illustrates how the scope of a patent disclosure 
differs from the scope of possible therapeutic equivalents of a 
lead product. Here, the scope of therapeutic equivalents would 
be defined by FDA’s requirements for follow-on products, e.g., 
under 505(j), 510(k), or BPCI Act. The solid circle represents 
patent scope, while the dashed circle represents product space 
containing suitable variant products that are equivalent to the 
lead product. For Complex Products, determining the metes and 
 
 271. See 35 U.S.C §112 (2012); see also U.S. PAT. & TRADEMARK OFF., 
MANUAL OF PATENT EXAMINING PROCEDURE §2164 (2018), 
https://www.uspto.gov/web/offices/pac/mpep/s2164.html [hereinafter MPEP]; 
see also In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). 
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bounds of what exactly is therapeutically equivalent, can be far 
more challenging than for conventional products. Developing 
any follow-on product involves the challenges and costs of 
identifying what attributes of the pioneer product affect 
equivalence, and how to measure, make, and control those 
attributes. For Complex Products, this technology and know-
how is either not within the reach of current science, or is not 
publicly known. 
After filing a patent and beginning clinical trials, an 
innovator typically develops technology that identifies critical 
quality attributes that can distinguish between equivalent a 
non-equivalent variations of their product, i.e., that can define 
the scope of FDA approvable therapeutic equivalents. For 
example, the innovator would have investigated a wide variety 
of structural and functional variants prior to selecting the final 
lead product for clinical testing. Moreover, manufacturing 
modifications likely lead to development of critical validation 
and characterization methods that are useful for predicting 
which batches and similar variants will have therapeutic 
properties.  
However, the innovator cannot necessarily obtain a patent 
claiming a product defined by these critical quality attributes. 
Such claims would be inherently anticipated—and thus 
unpatentable—over an earlier, pre-clinical disclosure of the lead 
product assuming the product had previously exhibited those 
same attributes. Although the innovator is typically first to bear 
the costs of identifying critical quality attributes associated with 
therapeutic equivalence, the innovator has no incentive to 
disclosure these critical attributes without the ability to obtain 
a patent. These costs are then redundantly borne out by each 
competitor who, in turn, have no incentive to disclose their 
insights. Redundant development efforts would be eliminated if 
the innovator had an incentive to disclose how much variation 
in structure, formulation, and manufacture is permissible, as 
well as the corresponding validation and characterization 
methods that identify equivalent variants. 
 A statutory mechanism should be created that rewards 
innovators with an extended period of exclusivity on their new 
Complex Product in exchange for disclosing information that 
enables others to predictably manufacture, identify, and obtain 
approval for an ANDA-type or similar-type therapeutic 
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equivalent.272 The period of extended exclusivity would be 
conditioned on the sufficiency of the disclosure. A sufficiently 
strong incentive may encourage the innovator to go beyond what 
is needed for approval of its lead product, and to further seek 
formal confirmation from the FDA that certain similars would 
indeed be approvable. The integrity of the system could be 
assured by permitting competitors to litigate over the sufficiency 
of the disclosure. 
This disclosure could take the form of a patent application 
submitted to the USPTO, or it could take the form of a public 
disclosure submitted to the FDA. In the form of a patent, the 
patent would recite claims to “an FDA-validated therapeutic 
equivalent” of the innovator’s lead product and providing critical 
quality attributes that are sufficient for obtaining an approvable 
equivalent.273 The FDA could facilitate such disclosures by 
cooperating with the innovator to establish critical quality 
attributes, and even indicate to innovators when suitable 
variations of their lead product would be approvable as well. 
Although permitting such patents could significantly extend 
patent exclusivity on branded compositions, the accompanying 
disclosure would contain enough data and know-how that any 
number of competitors could readily produce an approvable 
follow-on at minimal cost. If the disclosure is not adequate, the 
patent will be quickly disposed of. In the form of a disclosure to 
the FDA, the FDA could review it for sufficiency and then make 
it public in exchange for providing the innovator with a period of 
regulatory exclusivity or patent term extension.274 
 
 272. This statutory mechanism could take the form of a patent, a patent 
term extension, or regulatory exclusivity. 
 273. If the incentive takes this form, there may need to be a rule to exempt 
this claim format from inherency-type anticipation over prior disclosures of 
products having the same structure, but not used as a therapeutic equivalent 
and lacking an equivalency label. See 35 U.S.C §102 (2000); see also MPEP §§ 
2112 & 2131, https://www.uspto.gov/web/offices/pac/mpep/s2112.html. 
Enablement should require a showing of the FDA’s indication of approvability, 
in contrast with the conventional standard of In re Brana since, here, the 
proposed claims expressly invoke FDA action. Cf. In re Brana, 51 F.3d 1560, 
1568 (Fed. Cir. 1995) (“FDA approval . . . is not a prerequisite for finding a 
compound useful within the meaning of the patent laws.”). Additionally, the 
patent should include an accompanying disclosure sufficient for those of 
ordinary skill in the art to manufacture and obtain FDA approval of the claimed 
products. 
 274. See 35 U.S.C. §156 (2012) (outlining requirements for an extension of 
patent term). 
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The benefit of this proposed system is that redundant 
development efforts would be eliminated, and valuable 
information is made public. Dissemination of this information 
will benefit the pharmaceutical industry as a whole and advance 
technological understanding of challenging areas like Complex 
Products and medical nanotechnology. Although the cost of 
brand drugs may enjoy a longer period of monopoly pricing, the 
system would reduce overall costs to drug development, and 
ultimately enable a greater number of competitors to enter the 
market at once. 
CONCLUSION 
Complex Products involve regulatory and technological 
barriers to competitor entry. Specifically, the “chemical action” 
distinction of 21 U.S. Code § 321(h)(3) introduces uncertainty 
into the regulatory process and can lead to arbitrary distinction 
between FDA regulatory schemes. The “sameness” requirement 
of 21 U.S.C. §355(j) limits follow-on drug competition to generic-
type products that are bioequivalent and have the same active 
ingredient, route of administration, dosage form, and strength 
as a previously-approved reference product. This limitation is 
especially restrictive for Complex Products, for which showing 
bioequivalence of the “same” active ingredient may not be 
feasible. Lastly, because Complex Products involves technology 
that is not yet fully understood, competitors have the burden of 
identifying how structural aspects, manufacture, and 
therapeutic properties interrelate. This technology and know-
how is redundantly developed by the initial innovator and 
subsequent competitors, each of which presently have every 
incentive to keep the information confidential from the others. 
This Note suggests rethinking the chemistry-based 
requirements written into the FD&C Act and further proposes a 
new incentive to innovators to disclose data, tolerances, and 
know-how that will lower overall costs for development in the 
industry and improve scientific understanding of Complex 
Products. 
 
